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   Major Depression (MD) and Generalized Anxiety Disorder (GAD) are psychiatric 
disorders that arise from dysfunction of the core human capacities for emotion. 
Sapience is inextricably bound up with the potential for feelings of regret, worry and 
concern. When these emotions lead to clinically significant impairment or distress, they 
may result in one or both of the disorders of MD and GAD. The occurrence of MD and 
GAD in the same person, known as comorbidity, is remarkably high; substantially higher 
than would be expected by chance. 
 MD and GAD have been studied since the mid-20th century, resulting in a 
substantial body of literature. The personality trait of neuroticism is also known to 
correlate highly with these disorders. This project was designed to compare the 
etiological structure of MD and GAD using a range of psychosocial and genetic methods 
in three datasets, while also assessing the correlated trait of neuroticism. Results are 
used to inform theoretical formulation of an approximate model of comorbidity for the 
two disorders. 
 Psychosocial findings suggest that MD and GAD have similar relationships with 
most risk factors, and that neuroticism displays results consistent with it composing a 
portion of the liability to MD and GAD. 
 Efforts to detect specific genetic loci involved in the etiology of MD and GAD are 
modestly successful. Two genome-wide significant variants were found for MD (one 
	  already identified in the literature); two for GAD, and one for neuroticism. There were 
also a number of significant genomic regions for each outcome. 
 The use of aggregate genetic methods to estimate heritability based on 
genotypes was less successful. Estimation was only successful in one sample of the 
three, and produced modest estimates of heritability  (0.2-0.25) for MD and comorbid 
MD+GAD. Genetic correlation was estimated to be very high between neuroticism and 
MD. 
 Models of comorbidity are evaluated in light of these results, and a model 
comprising multiple liability distributions, one shared entirely by MD and GAD, and two 
additional correlated ones for the two disorders, with reciprocal phenotypic causation, is 
deemed most consistent with observed evidence.










The hallmark of humanity is what might be termed ‘sapience’, the ability to 
reason, feel, and be aware of one’s own awareness. It has fueled the mastery of 
humans over Earth, and enabled such achievements as walking on the moon, curing 
disease and shared experiences through all manner of storytelling media. As may be 
expected from a faculty with such potential, however, complexities arise. The precise 
constellation of values on all the myriad trait distributions that comprise the 
phenomenon of consciousness possessed by each human individual can be conceived 
as random draws from the probability space of all human minds. Thanks to genetic and 
experiential diversity, the values are, overall, slowly honed towards increased success 
in the world with each generation. Some of the traits shaped by this process in humans 
may include a strong ability to understand others as intentional agents, known as theory 
of mind (1) and a prosocial, cooperative motivation (2). This progress takes millennia, 
though, and trends that may have contributed to humanity’s early evolutionary success 
have consequences that cause distress in the state of contemporary society. One 
example is the metabolic efficiency that enabled early humans to store energy enough 
to survive even with scant nutritional resources; in present society, the easy access to 
food (and differing compositions of macronutrients) causes problems such as obesity in 
	   2	  
many people (3). An even more basic trend is the characteristic of human nature that 
leads one to care; caring about other people, evinced in the prosocial motivation, 
perhaps (2), as well as caring about the content of our experiences, and future goals 
and hopes. This drive to be emotionally involved with others and the content of our 
thoughts and perceptions played a crucial role in humanity’s ability to band together and 
protect one another from any number of physical threats, as well as seeking better and 
more enjoyable ways to interact with the world through an extensive accumulated 
culture. The unfortunate drawback of this capacity for caring, however, is that when 
people, events or circumstances deviate from our wishes, we may suffer emotional 
pain. “The pain that the world is not as you want it to be” (4).  
 It is important to note that emotion is not unique to humankind, evident for 
instance in the fact that the processing of different types of emotional vocalizations 
seems to occur in a similar fashion and in comparable brain areas in humans and dogs 
(5), whose most recent common ancestor lived between 90 and 100 million years ago 
(6). But emotions are more varied and elaborate in the sapient human race, a 
development necessary to achieve the culture that allows the extreme improvement in 
the quality from the earliest human lives to those in the present day. A useful definition 
may be: “Culture is an information-based system that allows people to live together and 
satisfy their needs.” (7). Culture, with respect to this broad definition, is not exclusively 
human either, given examples such as the idea of washing potatoes before eating them 
being passed down in generations of monkeys on the Japanese island of Koshima (7). 
But monkeys and other species capable of generating culture (such as apes, whales, 
dolphins, and elephants) may very well also qualify for sapience (8). Emotions, while not 
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unique to humans, are key to healthy functioning in humankind. Individuals who lack the 
capacity to experience emotions, due to a brain injury for instance, show imprudent 
judgment and often act very impulsively, causing many problems for themselves (9). Of 
course, even with a full range of emotions, troubles can arise. 
Separation from a loved one or being trapped in an awful situation may cause 
anguish to such extent that nothing seems worthwhile any longer. In certain people, 
such feelings may arise even without a clear contributing incident – we call this 
experience depression, and the most common form is major depression, a debilitating 
and frequently recurrent psychiatric disorder. Another distressing experience that can 
arise from human emotional faculties is the worry that can arise when one has been 
exposed to unpleasant experiences in life, and then expects more bad news to lurk 
around every corner. That state of constant concern in an individual of failing to meet 
their responsibilities, of not performing their job well or not protecting their loved ones. In 
some, the content of the worries changes often, but its presence is immutable. If the 
worry is persistent and problematic, we call it anxiety, and when the conceptual content 
of the anxiety changes in a free-floating manner, it may fall under the diagnosis of 
generalized anxiety disorder, a chronically aversive condition. As one may expect, 
occurrences of depressive and anxious feelings frequently dovetail, with worry causing 
more unhappiness, and episodes of depression sparking worries about any number of 
failing relationships, occupational roles or other topics. While anxiety and depressive 
disorders have been studied for ages, there is still little certainty about the exact 
etiological relationship between them. This manuscript details some efforts to unravel 
the intricate webs of misery woven between major depression and generalized anxiety. 








I.  Public health significance of anxiety and depressive disorders: 
While public health programs often are designed to reduce mortality, or deaths 
due to a particular cause, also important is the amount of non-lethal disease burden. 
This can include functional impairment, disability and economic consequences, and due 
in part to their contributions to these outcomes, the impact of depressive and anxiety 
disorders is great indeed.  
Major depression (MD) is the most common psychiatric disorder, and is nearly 
always associated with functional impairment, with almost 60% reporting severe or very 
severe role impairment (10). In terms of disability, depression and anxiety disorders are 
among the highest contributants to years lived with disability around the world, with MD 
the 2nd greatest cause (behind low back pain), and anxiety disorders 7th, above such 
problems as migraine, diabetes, and osteoarthritis (11). Generalized anxiety disorder 
(GAD), one of the most chronic anxiety disorders, is also a leading cause of workplace 
disability in the United States of America (USA), which of course affects economic 
productivity negatively, as well (12). In terms of overall economic effects, the impact of 
MD is substantial, costing $83.1 billion in the USA during the year 2000 (13), while 
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anxiety disorders had a cost of $42.3 billion in 1990 (14). GAD, in particular, has a 
pronounced negative effect on global well-being and life satisfaction (15).  
The effects of MD and GAD are not limited to reduced quality of life or 
productivity, as both disorders are associated with a range of medical conditions, some 
of which may be life-threatening. Depression increases risk for myocardial infarction 
(16), stroke (17), hypertension (18), and depressed individuals are approximately 
eleven times more likely to attempt suicide than those without depression (19). GAD is 
associated with a host of ailments as well, including pain conditions, such as arthritis, 
migraine, and back pain (20), a four-fold increase in risk of peptic ulcer disease (21), 
coronary heart disease (22), metabolic disorders such as diabetes (23), and chronic 
obstructive pulmonary disease (24). 
In addition to the public health consequences associated with MD and GAD 
individually, there is a high degree of comorbidity (occurrence of both diseases in the 
same person) between them. The sequelae of this comorbid state are often worse than 
either disorder individually.  Individuals with comorbid MD and GAD have higher 
impairment (25), increased disability, utilization of health care and suicidality (26).  
While MD and GAD both present significant public health concern, the two disorders 
have quite different histories in psychiatric research and practice. 
 
II.  Diagnostic History of MD: 
Depression has been characterized in many ways over the years, but there are 
similarities in its current characterization to behavioral maladies in the earliest recorded 
human history – for example, accounts of symptoms of insomnia, loss of appetite, and 
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impaired concentration in ancient Babylon (27). Perhaps one of the closest conceptual 
ancestors to our modern conception of depression is the ancient Greek idea of 
melancholia, though as described by Hippocrates it is substantially more pervasive than 
contemporary depression (28). Similar syndromes can be found in most periods and 
regions of human society, but much of the explanation was spiritual and religious in 
origin, claiming possession and witchcraft as causes. Eventually, theories about what 
we now called depression returned to roughly correspond to a conception of mental 
illness, the shift being best captured in what was the first concerted effort to detail the 
risk factors for and treatment of depression: The Anatomy of Melancholy (29). While the 
tome is at least as much literary as scientific, its breadth reflected the diverse and 
multifactorial nature of melancholy as it was conceived then.  
The transition from the diagnosis of ‘melancholia’ to the term ‘depression’ was in 
large part due to Emil Kraepelin, in his theoretical construct of manic-depressive 
insanity (including specifically depressive states) (30). Perhaps the fullest expression of 
the Kraepelinian approach to diagnoses via syndrome or longitudinal patterns of 
symptoms was realized in the eventual codification of the operationalized criteria for the 
diagnosis of psychiatric disorders into such reference texts as the Diagnostic and 
Statistical Manual of Mental Disorders (31, 32), which shares many common origins and 
similarities in content to the psychiatric portion of the International Classification of 
Diseases (33). DSM-IV criteria for major depression (or DSM-IV-TR criteria, which are 
the same) were administered in the datasets used for the present analysis to establish 
the MD diagnoses – see Tables 1 and 2. 
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Table 1. DSM-IV / DSM-IV-TR Criteria for Major Depressive Episode 
A. Five (or more) of the following symptoms have been present during the same 2-
week period and represent a change from previous functioning; at least one of the 
symptoms is either  
(1) Depressed mood or (2) loss of interest or pleasure. Note: Do not include 
symptoms that are clearly due to a general medical condition, or mood-
incongruent delusions or hallucinations.  
 (1) Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad or empty) or observation made by others (e.g., 
appears tearful). Note: In children and adolescents, can be irritable mood.  
(2) Markedly diminished interest or pleasure in all, or almost all, activities most 
of the day, nearly every day (as indicated by either subjective account or 
observation made by others)  
(3) Significant weight loss when not dieting or weight gain (e.g., a change of 
more than 5% of body weight in a month), or decrease or increase in appetite 
nearly every day.  Note: In children, consider failure to make expected weight 
gains.  
(4) Insomnia or Hypersomnia nearly every day  
(5) Psychomotor agitation or retardation nearly every day (observable by 
others, not merely subjective feelings of restlessness or being slowed down)  
(6) Fatigue or loss of energy nearly every day  
(7) Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick)  
(8) Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others)  
(9) Recurrent thoughts of death (not just fear of dying), recurrent 
suicidal ideation without a specific plan, or a suicide attempt or a specific plan 
for committing suicide  
B. The symptoms do not meet criteria for a Mixed Episode (see p. 335*).  
C. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning.  
D. The symptoms are not due to the direct physiological effects of a substance (e.g., a 
drug of abuse, a medication) or a general medical condition (e.g., hypothyroidism).  
E. The symptoms are not better accounted for by Bereavement, i.e., after the loss of a 
loved one, the symptoms persist for longer than 2 months or are characterized by 
marked functional impairment, morbid preoccupation with worthlessness, suicidal 
ideation, psychotic symptoms, or psychomotor retardation. 
 
* [Description of a Mixed Episode]  
A. The criteria are met both for a Manic Episode and for a Major Depressive Episode 
(except for duration) nearly every day during at least a 1-week period.  
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B. The mood disturbance is sufficiently severe to cause marked impairment in 
occupational functioning or in usual social activities or relationships with others, or to 
necessitate hospitalization to prevent harm to self or others, or there are psychotic 
features.  
C. The symptoms are not due to the direct physiological effects of a substance (e.g., a 
drug of abuse, a medication, or other treatment) or a general medical condition (e.g., 
hyperthyroidism). 
Note: Mixed-like episodes that are clearly caused by somatic antidepressant treatment 
(e.g., medication, electroconvulsive therapy, light therapy) should not count toward a 
diagnosis of Bipolar I Disorder. 
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Table 2. DSM-IV / DSM-IV-TR Criteria for Major Depressive Disorder, Recurrent 
 
A. Presence of two or more Major Depressive Episodes. Note: To be considered 
separate episodes, there must be an interval of at least 2 consecutive months in 
which criteria are not met for a Major Depressive Episode. 
B. The Major Depressive Episodes are not better accounted for by 
Schizoaffective Disorder and are not superimposed on Schizophrenia, 
Schizophreniform Disorder, Delusional Disorder, or Psychotic Disorder Not 
Otherwise Specified. 
C. There has never been a Manic Episode, a Mixed Episode, or a Hypomanic 
Episode. Note: This exclusion does not apply if all of the manic-like, mixed-like, 
or hypomanic-like episodes are substance or treatment induced or are due to the 
direct physiological effects of a general medical condition. 
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III.  Diagnostic History of GAD: 
The origins of anxiety as a cognitive state are perhaps even older than 
depression, as it is associated with physiological arousal and stress responses in 
general, such as the fight-or-flight response (34), which is present in most vertebrates 
and other animals. Anxiety, as a counterpoint to depression, is commonly understood to 
have some adaptive value at moderate levels, including reducing risk of accidents (35), 
and even fostering trust in others (36). It is also, as mentioned earlier, intimately related 
to the human capacity for reasoning, with some even claiming that anxiety is the default 
state of the human brain (when not suppressed by regulatory signals) (37), and that 
anxiety evolved in a close relationship with intelligence (38). Nevertheless, too much 
anxiety is clearly pathological, and this has been known to history for nearly as long as 
depression’s troubles: anxiety symptoms can be seen in the texts of Hippocrates 
(especially phobia – of flute music at night!) (39), and the Anatomy of Melancholy also 
contains descriptions of anxiety (29). But the historical conceptions of anxiety did not 
approach the modern understanding of the condition until more recently.  
Neurasthenia, first described by George Miller Beard in 1869, was quite a 
heterogeneous condition that encompassed many contemporary anxiety symptoms 
(40), among its many other diverse symptoms. Anxiety also formed a basis for Freud’s 
theories, though he refined his definition of anxiety over time (41). Kraepelin wrote on 
anxiety as well, calling it the most frequent of all abnormal distressing effects (42), 
though he did not write extensively on anxiety as a separate diagnoses from other 
conditions. After the first two iterations of the DSM focusing on psychodynamic theory, 
with anxiety disorders being designated primarily by the terms ‘psychoneurotic 
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disorders’ and ‘neuroses’ (43), the creation of GAD as an individual disorder in DSM-III 
came about due to differences in psychopharmacological treatment (44). While there 
have been changes to the diagnoses since its inception, primarily with regards to 
minimum duration and hierarchy with other disorders, the core of the condition: chronic, 
context-agnostic anxiety and worry that is difficult to control, persists. See Table 3 for 
the DSM-IV / DSM-IV-TR criteria used in this study.  
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Table 3. DSM-IV / DSM-IV-TR Criteria for Generalized Anxiety Disorder 
 
A. Excessive anxiety and worry (apprehensive expectation), occurring more days 
than not for at least 6 months, about a number of events or activities (such as 
work or school performance).  
B. The person finds it difficult to control the worry.  
C. The anxiety and worry are associated with three (or more) of the following six 
symptoms (with at least some symptoms present for more days than not for the 
past 6 months). Note: Only one item is required in children.  
 (1) Restlessness or feeling keyed up or on edge  
(2) Being easily fatigued  
(3) Difficulty concentrating or mind going blank  
(4) Irritability  
(5) Muscle tension  
(6) Sleep disturbance (difficulty falling or staying asleep, or restless 
unsatisfying sleep)  
D. The focus of the anxiety and worry is not confined to features of an Axis I 
disorder, e.g., the anxiety or worry is not about having a Panic Attack (as in Panic 
Disorder), being embarrassed in public (as in Social Phobia), being contaminated 
(as in Obsessive-Compulsive Disorder), being away from home or close relatives 
(as in Separation Anxiety Disorder), gaining weight (as in Anorexia Nervosa), 
having multiple physical complaints (as in Somatization Disorder), or having a 
serious illness (as in Hypochondriasis), and the anxiety and worry do not occur 
exclusively during Posttraumatic Stress Disorder.  
E. The anxiety, worry, or physical symptoms cause clinically significant distress 
or impairment in social, occupational, or other important areas of functioning.  
F. The disturbance is not due to the direct physiological effects of a substance 
(e.g., a drug of abuse, a medication) or a general medical condition (e.g., 
hyperthyroidism) and does not occur exclusively during a Mood Disorder, a 
Psychotic Disorder, or a Pervasive Developmental Disorder. 
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IV.  History of Neuroticism: 
Neuroticism is presently understood as a foundational factor in an individual’s 
personality, associated with the frequent occurrence of distressing emotions such as 
anxiety, guilt, anger, envy, frustration and sadness (45). Its origins, (and those of other 
theories of defining personality features) can again be traced to Hippocrates, who 
developed the (even more ancient) idea of four primary temperaments (or humors) into 
a medical theory, though not all of the writings attributed to him include the theory (46). 
The four temperaments included sanguine, choleric, phlegmatic and melancholic, 
corresponding to four substances believed to be present in the human body (29). The 
traits of the melancholic temperament: despondent and serious, bear the most 
resemblance to modern neuroticism.  
The most well-known user of the term neuroticism is likely Hans Eysenck, who 
introduced a two-factor model of personality in his work the Dimensions of Personality 
(47) – this was later expanded to the more well-known three-factor model (48). He also 
made reference to the ancient four-temperament theory, by noting that combinations of 
neuroticism and extraversion (his other initial personality factor) produced similar results 
– e.g. high neuroticism and low extraversion corresponded to the melancholic 
temperament. These personality traits, like temperaments, were considered to be 
inherent features of the individual, and essentially stable over time. While other 
personality theories later gained comparable acclaim, such as the five-factor model e.g. 
(49), Eysenck’s neuroticism appears largely unchanged (as does extraversion) in most 
of them, reflecting the relevance of these dimensions in describing personalities. While 
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neuroticism, as a personality trait, may seem an odd inclusion in this investigation of MD 
and GAD, the connection is actually quite close; high levels of neuroticism are 
associated with a range of psychopathological outcomes (50), including all mood 
disorders, anxiety disorders, and substance use disorders. Indeed, Eysenck’s 
conception of neuroticism may very well have been an effort to characterize a latent 
continuum of liability to affective disorders. The relationship of MD and GAD to 
neuroticism has fittingly been theorized to be due to common etiology, for instance, 
there is evidence that latent “genetic factors underlying individual differences in 
neuroticism exhibit significant overlap with the genetic risk for major depression, 
generalized anxiety disorder, panic disorder, and the phobias” (51). Eysenck anticipated 
this, too, having conducted research that showed that when a number of different 
assessments of various aspects of neuroticism were given (which successfully 
discriminated ‘normal and neurotic children’), the general factor explaining overall 
variance was found to have a heritability of 0.81, suggesting neuroticism was mostly 
genetic (52, 53). This is a higher figure than more recent biometrical estimates, 
however, summarized in section VIII below. See Table 4 for some sample items used to 
measure neuroticism in this study. 
 
V.  Epidemiology of MD: 
As mentioned in Section I, MD is one of the most prevalent single mental 
disorders, with lifetime prevalence in most countries falling between 8-12% (54). One of 
the most consistent findings in its assessment is a much higher prevalence in women 
than in men, throughout the world (55).  The cause of this sex difference may be partly 
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physiological, but there is also evidence that structural gender discrimination such as 
the wage gap between men and women in the United States of America (USA) 
contributes to increased rates of MD in women (56). Lifetime prevalence is highest in 
the USA at 17% (54), but is difficult to assess reliably in some other countries, such as 
China. MD in China shows lower estimates from 3.6% (57) to 6.5% (58), depending on 
the region surveyed, though there is some evidence of underreporting in MD in China 
due to a cultural tendency to deny depression or focus on physiological symptoms (59). 
Therefore, it is likely that the true prevalence is somewhat higher, around 8% in Chinese 
women.  
It is also clear that there are a number of risk factors with a powerful impact on 
the risk of developing MD. Perhaps the strongest are social relationships and stressful 
life events. The connection between romantic relationships and depression seems 
intuitive. That is, being in a fulfilling relationship is a goal for many people, and indeed 
marriage (the most well-studied type of romantic relationship) is long known to be 
protective against depression (60). Even among college students, being in a committed 
dating relationship seems to have some protective effect against psychopathology (61), 
though the impact in that particular study was not significant for depressive symptoms in 
males.  
Stressful life events, a catch-all term for common generally aversive experiences, 
such as death of a loved one, physical or sexual abuse, romantic separation or financial 
difficulties, are highly associated with the onset of depression (62). There are differential 
effects on how depressogenic (depression-causing) an individual event may be 
however, based on context, and what type of impact it may have; events that involve 
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loss or humiliation tend to be the most depressogenic (63). Certain severe events also 
qualify as traumatic events, and, unfortunately, these are quite common. The majority of 
the world’s population, as well as a majority of most countries worldwide have 
experienced at least one traumatic event, though the precise prevalence varies from 
country to country, such as 52.5% of individuals in China, to 82.7% of individuals in the 
USA (64). 
There are, of course, many other risk factors for MD, including low 
socioeconomic status (SES) or poverty (65), use of some psychoactive substances, 
such as alcohol (66) and methamphetamines (67), and more, but the effects of social 
support and life stress are among the strongest predictors of MD. 
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Table 4. Sample Items from Neuroticism Scales in CONVERGE* and S4S** 
Sample: Items: 
CONVERGE* Would you call yourself a nervous 
person? 
Do you ever feel "just miserable" for no 
reason? 
Does your mood often go up and 
down? 
S4S* I see myself as someone who is 
relaxed, handles stress well. 
[Reversed] 
I see myself as someone who worries a 
lot. 
I see myself as someone who is 
emotionally stable, not easily upset. 
[Reversed] 
*China, Oxford, and VCU Experimental Research on Genetic Epidemiology – Items 
presented are English translations from the Mandarin Chinese original items. Yes/no 
responses. 
** Spit for Science, the VCU Student Survey – Items rated as 1-5 for agreement with the 
statement (from ‘disagree strongly’ to ‘agree strongly’)
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VI.  Epidemiology of GAD: 
GAD is less common than MD, but its often chronic nature renders it a lifetime 
burden to many who suffer from it. In the USA, lifetime prevalence is 4.2-12.7% 
depending on required minimum duration, though notably a number of clinical features 
(such as onset, persistence, severity, and comorbidity patterns) are similar between 
shorter duration cutoffs and the DSM-IV duration requirement of 6 months (68). Like 
MD, anxiety disorders such as GAD are about twice as prevalent in females as males, 
and are less common among individuals in Asian cultures than in Western cultures (69). 
The sex difference in GAD appears to be partially mediated by wage disparity between 
men and women in the USA, if to a somewhat less pronounced degree than in MD (56) 
The prevalence of GAD in China is estimated at slightly over 1% (70), though again, 
there is evidence of a certain reluctance in Chinese individuals to disclose psychological 
symptoms during face-to-face interviews (71). 
Risk factors for GAD are quite similar to those of MD; romantic relationships such 
as marriages are protective against GAD, though this effect is proportional to the quality 
of the marital relationship, and relationships with other family members are still 
important as well (72). Stressful life events, such as natural disasters, childhood abuse, 
and family problems, seem to have a strong impact on the onset and maintenance of 
GAD (73). The events that have elements of loss or danger are particularly likely to 
predispose to GAD (63), which is intuitive when you consider the defining feature of 
worry – being exposed to danger or threat is clearly anxiogenic. As mentioned in the 
last section, traumatic events such as these are far from rare, with a majority of people 
worldwide reporting at least one traumatic experience (64) Substance use can also 
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contribute to GAD, including common stimulants such as nicotine (74), and caffeine 
(75).  
 
VII.  Relationship of Neuroticism to anxiety and depressive disorders: 
Neuroticism is perhaps the most frequently assessed personality trait, and with 
good reason. Levels of this trait are associated with psychopathological outcomes quite 
strongly (50), and could therefore be used as a trait-level index of susceptibility to 
internalizing disorders. It is not, however, to be properly thought of a ‘risk factor’ for 
internalizing psychopathology in the usual sense, as there is strong evidence that 
common etiological origins are shared between neuroticism and such disorders as MD 
and GAD. Firstly, the conceptual similarity between neuroticism and the disorders of MD 
and GAD is evident even in their composite measurement instruments (compare 
diagnostic criteria from Tables 1-3 with sample neuroticism items in Table 4). Latent 
additive genetic factors contributing to neuroticism appear to account for a sizeable 
portion of the genetic variance of most anxiety and depressive disorders (51). Latent 
unique environmental factors have also have been shown to overlap between 
neuroticism and MD, as well as all anxiety disorders save for specific phobias (51). This 
indicates that, rather than being a separate temperamental characteristic whose 
presence aggravates the psychological equilibrium of a person, and tends to plunge 
them into depression or anxiety, it instead more likely constitutes a portion of whatever 
baseline vulnerability there may be to internalizing psychopathology. In other words, 
neuroticism is better classified as ‘diathesis’ than ‘stress’ (76).  
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However, investigation of neuroticism as a separate construct from mood and 
anxiety disorders may be useful, as levels of the trait are often fairly stable from early 
life, and therefore may precede the onset of many disorders, including not just 
psychiatric ones but also such medical conditions as cardiovascular disease (77). One 
theory (which dates at least to Eysenck himself), suggests that neuroticism is the 
dispositional manifestation of the level of activity in the limbic system, the reactivity of 
the sympathetic nervous system, and corresponds to sensitivity to environmental stimuli 
(78) Indeed, neuroticism has been found to prospectively predict the onset of mood and 
anxiety disorders (more so than other correlated psychiatric outcomes, such as 
substance use disorders), and especially comorbid mood and anxiety disorders (79).  
 
VIII.  Biometrical Modeling of MD, GAD and Neuroticism: 
The high prevalence, and debilitating effects of MD and GAD have led many 
researchers to seek better understanding of the contributions of different types of 
factors to their variation in the populace. Neuroticism, as a personality trait easily 
measured via self-report, is also well-studied. Due to the evidence of common 
associated factors between the three, there have also been efforts to characterize the 
degree of overlap. Perhaps the greatest contributions to the quantification of latent 
factors in these constructs are from the twin methodology, comparing trait correlations 
among monozygotic and dizygotic twin pairs to assess the contributions of latent 
additive genetic factors to the trait.  
It is worth noting that an implicit assumption in many conceptions of MD and 
GAD is that of a liability model (80), where there is an continuous distribution of 
	   21	  
propensity to MD and another distribution of propensity to GAD. Under this model, 
disease occurs when a person’s liability score reaches a certain threshold in that 
distribution, but there is nevertheless some (recondite) significance in smaller increases 
in liability, often in terms of an increase in risk. 
The heritability of MD as assessed by twin studies is approximately 0.42 in 
women of European ancestry, and 0.29 in European men, with a genetic correlation of 
0.63 between the sexes (indicating a portion of genetic influences acting in a sex-limited 
fashion), and when constrained to equality, the estimated heritability in both sexes 
together was 0.38 (81). These estimates differ under certain circumstances, for instance 
in densely affected pedigrees with high risk of MD, heritability has been estimated at 
0.67 (82). The heritability of MD in other populations, such as the Chinese population, is 
understudied in twin work, though there is some evidence that heritability is comparable 
between European and East Asian populations (83).  
Heritability of GAD is often estimated in about the same range, at about 0.32 
(84), though this appears not to differ between the sexes as the MD estimate does (85). 
There is evidence, however, of a threshold difference between men and women, 
however (86), suggesting that, though the contributions of genetic factors may be 
similar in both sexes, the level of liability required to develop GAD is lower in women 
than in men, which is consistent with the higher prevalence of GAD in women (69). 
Again, GAD is understudied in populations of non-European descent, and therefore twin 
estimates of GAD heritability in other populations such as that of China are not readily 
available.  
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Neuroticism, though a personality trait rather than a psychiatric disorder, is 
frequently estimated via twin studies as having a heritability of about the same 
magnitude as MD and GAD, or slightly higher, ranging from about 0.40-0.60 (87). It 
does not seem as though there are appreciate sex differences in the heritability of 
neuroticism, however, unlike MD (88). Neuroticism, like GAD, has not been the subject 
of sufficient biometrical research in non-European populations, so estimates of 
heritability in Chinese populations are unavailable. 
Given the high comorbidity between MD and GAD, as well as the strong 
correlation between both disorders and neuroticism, it may perhaps be expected that 
there is overlap in the latent factors involved in their etiology. Most biometrical studies of 
MD and GAD find a correlation in their genetic factors indistinguishable from unity (86, 
89-91), though at least one has found an estimate of high (0.74 genetic correlation) but 
not total overlap in males (91). Notably, the latent environmental correlation is more 
modest, and seems to be higher in males at 0.65 (91), than females at 0.40 (91, 92).  
Neuroticism also seems to display some common genetic and environmental 
influences with MD and GAD. Latent genetic correlation with neuroticism is estimated at 
approximately 0.2 with MD, and 0.24 with GAD (51). Latent unique environmental 
correlation with neuroticism is somewhat smaller, at about 0.15 with MD, and 0.16 with 
GAD (51). This may seem surprisingly low, compared with the strong phenotypic 
relationship between neuroticism and both MD and GAD, but notably, it has been 
estimated that there is no latent genetic variance in neuroticism that is unshared with 
mood and anxiety disorders – i.e. all of neuroticism’s genetic influences also predispose 
to MD, GAD or other anxiety disorders (51).  
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IX.  Genotypic studies of MD, GAD and Neuroticism: 
More recently, investigations into these disorders and neuroticism have begun 
using measured genetic information as technology and statistical methods develop in 
concert. To date, only a relatively small amount of understanding has been gained 
through these sorts of investigations, but the results suggest that progress will be 
incremental in these (and most) psychiatric outcomes of interest. Future discovery of 
any as yet unknown single genetic variants (or single genes) explaining a majority of 
trait variance in any of MD, GAD or neuroticism is, based on existing evidence, unlikely. 
Nevertheless, important insights about biological mechanisms of these disorders are 
more often the goal of these studies, and in this respect there has been some success.  
Perhaps the most direct interrogation of the human genome for etiologically-
relevant variation is the genome-wide association study (GWAS). In brief, this compares 
individuals’ unique genotypes at a great many polymorphic sites (loci where multiple 
alleles, or alternative nucleotide sequences for the same portion of a chromosome) in 
the genome to their phenotypic values at whatever the trait of interest may be. If there is 
a statistical relationship that is sufficiently strong, and it is borne out in subsequent 
investigations (called replication), the relevant variant may be considered to be a marker 
of a genomic region likely to be involved in the outcome. GWAS have been performed 
on MD, GAD, and Neuroticism many times, but for various reasons, only in the last 
couple years have there been truly promising results.  
Notably, the first genome-wide significant (after multiple testing correction for the 
vast number of polymorphic variants included in the average GWAS) loci for MD were 
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found in one of the samples used in this paper; the all-female Han Chinese 
CONVERGE sample (93). GAD has been examined in GWAS less frequently, but one 
recent study found a variant that reached significance for a GAD symptom score in the 
primary analysis, but did not replicate (94); this study also was conducted on one of the 
relatively few samples composed of Latino individuals. Neuroticism has had somewhat 
better success, with a large meta-analysis finding 11 associated variants, including two 
that were attributable to previously characterized inversions (a type of genomic 
rearrangement in which the normal sequence order is reversed; these are especially 
difficult to detect using standard mapping methods), due in large part to greatly 
increased sample size over most similar studies (95).  
Due to the difficulty and expense in assessing clinical disorders such as MD and 
GAD in a large number of individuals as GWAS requires for adequate power, many 
researchers have opted to evaluate genetic associations for related phenotypes with 
close conceptual and statistical relationship with the psychiatric disorders. In the same 
study that found the neuroticism loci above, the outcome of depressive symptom count 
was also tested, resulting in 2 independent variants (95). Another study used anxiety 
sensitivity, a dispositional fear of arousal sensations, as a proxy for GAD, finding a 
significant result despite a comparatively small sample size (96). An alternative strategy 
involves pooling of multiple related outcomes to maximize genetic variance, resulting in 
a significant result for an ‘any anxiety disorder’ dichotomous phenotype, and another for 
a factor-analytic anxiety score in a meta-analytic study assessing not only GAD, but 
also phobias and panic disorder (97). A brief summary of genes that contain associated 
variants with any of these outcomes is listed for reference in Table 5. 
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Table 5. Previous Genetic findings from GWAS in MD, GAD, and Neuroticism 
Outcome Genes Variants Reference 
















































































LOC152225 rs1709393 (97) 
Anxiety Factor 
Score 
CAMKMT rs1067327 (97) 
* – result did not replicate.
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In addition to GWAS, a genotypic analogue to twin-based heritability estimation is 
possible through the use of such techniques as Genomic Complex Trait Analysis (99) or 
GCTA, and Linkage Disequilibrium Score Regression (100) or LDSC. These methods 
use different strategies to estimate the overall level of variance attributable to additive 
genetic effects in measured genetic variants, and can also estimate genetic correlation 
between pairs of traits. See Chapter 4 for a more detailed explanation of each. MD 
heritability has been estimated at 0.41 (transformed to the liability scale) using LDSC 
(100), which is comparable to twin estimates. This last finding is somewhat anomalous, 
however, given the estimate is comparable to, or perhaps in excess of the coed twin 
estimate of 0.38 for MD heritability (81); the twin estimate should represent an upper 
bound on the range of snp-based heritability for a given trait, due to including, in 
addition to all additive genetic effects of any magnitude (101), any unmodeled 
dominance or epistatic effects (102), interaction between additive genetic effects and 
shared environmental effects,  and correlation between additive genetic effects and 
unique environmental effects (103). Also see the discussion of Chapter 4. 
GAD has not notably been assessed thus far with these methods in its 
dichotomous diagnostic form, but a GAD symptom score has demonstrated a low 
heritability of 0.07, using a method similar to GCTA (94). Neuroticism appears to have a 
low heritability as estimated by these methods as well, about 0.09 (using LDSC) in 
European populations (95), and 0.10 (using GCTA) in the Chinese population (104). 
Similarly meager estimates are found for depressive symptoms using LDSC, at 0.05 
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(95), the any anxiety disorder outcome using GCTA, at 0.14, and the anxiety factor 
score, also using GCTA, at 0.11 (97).  
While the differences between empirical estimates of heritability generated by 
GCTA and LDSC and latent estimates produced by biometrical studies are troubling to 
the extent that they are both designed to estimate ‘additive genetic heritability’, they 
properly include different sets of genetic effects. As mentioned above, the twin 
estimates include the effects of rare variants, genetic interactions, and gene-
environment interplay, among other sources of variance, whereas the genotype-based 
methods include only the genetic effects of variants provided as input. Therefore, the 
heritability estimates provided by GCTA and LDSC are often lower bounds of true 
narrow-sense heritability (variance due to all and only additive genetic effects). 
Essentially, the heritability from genotypic methods is, generally, ‘narrower’ than narrow-
sense heritability, and biometrical heritability estimates are often ‘broader’ than narrow-
sense heritability. 
Even in the absence of sufficient sample size to estimate genetic correlation 
using measured genotypes, which can be substantial for both LDSC and GCTA, genetic 
relationships between phenotypes can be evaluated using polygenic scoring methods, 
such as the Purcell method (105), which prunes association results for variants using 
linkage disequilibrium (LD) to select a set of independent loci that are filtered by 
significance to predict an outcome, and LDpred (106), which uses a Gaussian mixture 
prior parameter (proportion of causal effects) and empirical estimation of heritability to 
infer the posterior mean effect sizes (weights) of variants using a Markov Chain Monte 
Carlo Gibbs Sampler. Early polygenic scoring work suggested MD risk scores could 
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predict anxiety symptoms to some degree (107), and more recently, neuroticism scores 
have successfully predicted MD, even using a European discovery neuroticism sample 
to predict into a Chinese validation sample (104). While virtually all polygenic prediction 
results explain minimal fractions of the total trait variance in any outcome, this is a still a 
fruitful area for meaningful contributions to be made by studies with insufficient sample 
sizes for genotypic heritability estimation. 
 
X.  Scope of dissertation project: 
The overall story of MD and GAD seems to suggest they both developed in 
concert over the course of human evolution, and have been present in various guises 
throughout recorded history. While similarities are present between the two disorders in 
both specific and latent risk factors, including genetic and environmental influences, it is 
unclear to what extent the genetic elements are distinguishable between MD and GAD. 
In addition, the majority of psychosocial risk factors associated with the disorders act 
similarly on both (for instance, strong relationships are protective, stressful life events 
increase risk), though there is evidence of discriminatory effect for certain carefully 
measured environmental experiences, such as the specific consequences of certain 
types of stressful life events; events with elements of danger are especially anxiogenic, 
humiliation events are especially depressogenic, while loss events predispose to both 
disorders (63). Notably, neuroticism appears to be a relatively stable dispositional trait 
that constitutes a portion of the shared variance of MD and GAD. 
To characterize the individual and communal influences on MD, GAD and 
neuroticism, the remaining chapters of this dissertation will address a comprehensive 
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range of psychosocial, genetic and genomic analyses conducted using the datasets 
available, which have overlapping strengths and limitations. 
The China, Oxford, and VCU Experimental Research on Genetic Epidemiology 
(CONVERGE) Study is a clinically-ascertained genetic study designed to investigate 
Major Depression. It is composed of 5,303 recurrent MD cases and 5,337 screened 
controls, all women with full Han Chinese ancestry. There are extensive questionnaires 
in this study, but MD cases and controls received different assessments; the most 
important consequence of this design in terms of this project is that GAD is only 
assessed in MD cases. The Molecular Genetics of Schizophrenia (MGS) study is a 
case-control study of Schizophrenia, but has the useful quality of having full 
psychopathological assessment information on all their European-ancestry controls, 
which constitute the portion of the sample used for this study. The study does not 
include information about other sub-clinical phenotypes, however, such as social 
relationships, neuroticism or stressful life events. 
Spit for Science (S4S), the Virginia Commonwealth University Student Survey, is 
a cohort sequential study of undergraduate students at VCU. Data in this project comes 
from cohorts 1, 2 and 3. There is a wide range of information on the participants, and 
there are individuals of both European and East Asian ancestry (among others), but 
since the population comprises emerging adults who are attending college, there is low 
prevalence of clinically significant disorder, and therefore the majority of relevant 
information is on risk factors and continuous correlates of MD and GAD. 
For brief summary details on each sample, please refer to Table 6. 
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In Chapter 2, comparative associations between well-established risk factors for MD, 
GAD and neuroticism will be assessed to determine which are selectively predictive for 
one outcome over another, and which seem to have similar impact on multiple 
outcomes.  
In Chapter 3, leveraging the three samples introduced above, results will be 
displayed from gene discovery efforts designed to determine if any single variant or 
genomic interval shows a statistically notable association with MD, GAD or neuroticism, 
and, subsequently, whether significant associations for one outcome are suggestively 
significant for the others as well. 
In Chapter 4, the findings of biometrical genetic studies will be tested, attempting 
to estimate genotypic heritability of MD, GAD and neuroticism and genetic correlation 
between them. Polygenic scores will be used to assess the degree to which 
interprediction between outcomes is successful. A specialized method will assess the 
degree of heterogeneity of GAD-within-MD and MD-within-GAD to check for asymmetric 
relationships.  
Identification of risk factors constituting the risk profiles of MD, GAD and 
neuroticism with increasing specificity enables a progressive account of the extent to 
which they overlap in each etiological domain, including both genetic and 
environmental. 
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Table 6. Sample characteristics of datasets 





CONVERGE 10,099 CIDI (108), VATSPSUD (109), BFI (110) Illumina HiSeq (111) 
MGS 2,612 CIDI-SF (112) Affymetrix 6.0 (113) 
S4S 7,532 SCL-90 (114), BFI (110),  LEC(115) Affymetrix Biobank (116) 
CIDI: Composite International Diagnostic Interview; VATSPSUD: Virginia Adult Twin 
Study of Psychiatric and Substance Use Disorders; BFI: Big Five Inventory; CIDI-SF: 
Composite International Diagnostic Interview, Short Form; SCL-90: Symptom Checklist 
90; LEC: Life Events Checklist.








I.  Methods: 
Samples: Psychosocial risk factors are available in CONVERGE and S4S 
samples, and include marital status, social support, and stressful life events in 
CONVERGE, as well as relationship status, relationship satisfaction, involvement in 
social activities, social support, and stressful life events in S4S. For S4S, there are 3016 
individuals of European ancestry (EUR), 557 individuals of East Asian ancestry (EAS), 
2929 males, and 4603 females in cohorts 1-3, which were the subset included in these 
analyses. S4S cohort 1 had responded to 3 years of survey follow-up, cohort 2 had 
responded to 2 years of survey follow-up, and cohort 3 had responded to 1 year of 
survey follow-up when data was assembled for these analyses. 
Variables: Outcomes in CONVERGE include BFI neuroticism (110), which was 
standardized, MD status, and a dichotomous outcome of MD+GAD comorbidity versus 
MD controls – a ‘case-control’ test of MD+GAD status. GAD is not assessed in controls, 
but due to the substantial screening for MD in CONVERGE, and the high frequency of 
comorbidity between MD and GAD, the number of MD controls who have unassessed 
GAD is likely to be minimal, and if present, should only reduce power modestly. 
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Outcomes in S4S include an abbreviated 3-item BFI neuroticism score (110), and 
a sum score of 4 SCL-90 depressive symptoms (114), both of which were standardized. 
The psychometric properties of the shortened scales retain passable reliability 
compared to extended scales. Alpha levels of the shorter and longer (8-item) 
neuroticism scales are 0.695 and 0.813, respectively. Alpha levels of the shorter and 
longer (9-item) depressive symptom list are 0.917 and 0.94, respectively. Unfortunately, 
the shorter scales were the only assessment given to the majority of the sample, so 
choice is limited. 
Predictors in CONVERGE include demographic information on marital status 
(choices included: ‘Married’, ‘Separated’, ‘Divorced’, ‘Widowed’, and ‘Never married’), 
which was made into a marriage termination variable of ‘Divorced/Separated’ versus 
‘Married’; a social support scale (117), which was standardized; a stressful life events 
checklist, adapted from the Virginia Adult Twin Study of Psychiatric and Substance Use 
Disorders (VATSPSUD) including age of occurrence (109), which was divided into 
childhood (before age 17) and adulthood (after age 17, for this purpose) events, and 
standardized separately. 
The stressful life events variable in CONVERGE was constructed from a count of 
the different events endorsed by each individual in their lifetime. The events included 
were: death of a spouse, child or sibling; divorce or long-term separation due to marital 
difficulties; unemployment for more than one month; fired from a job; major financial 
crisis; problems with police or required court appearance; serious illness; life-
threatening accident; fire, flood or natural disaster; witnessed someone being badly 
injured or killed; rape; physical assault; physically abuse as a child; serious neglect as a 
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child; threatened with a weapon, held captive or kidnapped; and any other terrible 
experience. 
Predictors in S4S include an abbreviated relationship satisfaction scale (118); a 
checklist of participation in group activities, including sports, fraternities/sororities, 
school-related, community, and church, which was standardized; a social support scale 
(119), which was standardized; and a checklist of stressful life experiences (115), which 
were summed for a lifetime count. 
The stressful life events variable in S4S was constructed from a count of the 
different events endorsed by each individual in their lifetime, whether before or during 
college. The events included were: broken engagement or steady relationship; 
separation from other loved one or close friend; serious illness or injury; burglarized or 
robbed; trouble with police; laid off or fired from a job; major financial problems; serious 
housing problems; serious difficulties at school; someone emotionally close passed 
away; mother or father had a serious illness or injury; someone else close to you had a 
serious illness or injury. 
Covariates for both CONVERGE and S4S were used to adjust for the effects of 
demographic factors, when appropriate. Age at assessment was included in all 
analyses, as well as sex when more than one sex was included in a test (CONVERGE 
is all female, for instance, so analyses with that sample did not include a sex covariate). 
SES was adjusted for using educational attainment as a proxy. In CONVERGE, this 
was directly assessed in the demographic interview, whereas in the S4S sample, given 
participants are still in college, the educational attainment of their parents was used 
instead. Finally, for those questions in S4S that were answered more than once in 
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follow-up surveys, number of occasions is included as a covariate as well, to control for, 
as an example, the increased exposure time a participant in S4S had to possibly 
experience a stressful life event in their third year of college compared with someone 
who only responded to the survey in their first year. 
A brief aside is perhaps worthwhile to discuss the decision to consider 
neuroticism as an ‘outcome’ in these analyses. While the term ‘outcome’ is used 
throughout this manuscript, this should not be taken to imply that neuroticism is only 
subject to causal effects of other variables and has no causal action itself. ‘Predictor’ 
and ‘outcome’ are effectively useful shorthand terms to denote ‘independent variable’ 
and ‘dependent variable’ in analyses. This arrangement was selected because the 
primary interest is in the influence of predictive factors on neuroticism score, along with 
MD and GAD status. This is true throughout the manuscript, though in certain cases the 
implication is more pernicious. Neuroticism, as described earlier, is a dispositional trait 
of individuals that has high temporal stability over the life course. One of the key 
requirements for a causal relationship in the physical universe (so far as we know) is 
temporality – the cause must precede the effect. While some of the predictors, such as 
stressful life events, can be traced to a particular moment, others, such as neuroticism, 
persist diffusely throughout the lifespan, arising in concert with the rest of an individual’s 
personality at some unknown (perhaps unknowable) moment. Temporality of 
neuroticism in general is not clear. 
Moreover, prospective studies have shown that it acts as outcome and predictor 
both, in different ways. Neuroticism can change to some extent as a result of life 
experiences, for example, befriending new people tends to lower neuroticism over time, 
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whereas breaking up a longstanding relationship with a friend or relative increases 
neuroticism (120). Conversely, high neuroticism individuals have a higher likelihood of 
experiencing a variety of stressful life events (121). Therefore, while the terms 
‘predictor’ and ‘outcome’ will be used throughout, it is with the understanding that causal 
links may very well be present in both directions, and the statistical correlation is the 
central interest, rather than directionality. 
Analyses: Hierarchical regressions were conducted on each combination of 
predictor and outcome in CONVERGE and S4S. Initially, only predictor and outcome 
were included in the regression, followed by a step in which covariates were added, and 
finally multivariate analyses including all predictors in the sample to estimate overall 
fully-adjusted effects. Given past literature’s suggestions of sex differences in the 
relationship between risk factors and MD, GAD and neuroticism (61, 122, 123), and 
potential differences in presentation between European and East Asian populations 
(59), the S4S analyses were also performed stratified by sex and ancestry. The 
ancestry groups were limited to EAS and EUR for (broadly) within-ancestry comparison 
of results between EAS and CONVERGE, and between EUR and MGS (in other 
chapters). These analyses were tests of theory derived from past literature, and 
concerned more with distinguishing effects between groups and outcomes than on 
significance, so multiple testing correction was not applied. 
 
II.  Results: 
Results from the psychosocial predictors in CONVERGE can be found in Figures 
1-4. In progressive models with added covariates and multiple predictors the effect 
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sizes are attenuated but still robustly significant. This attenuation is expected due to the 
correlation between variables; for instance, some of the harmful impact of stressful life 
events on these outcomes may be due to interpersonal conflict, and this same conflict 
may result in reduced quality of social relationships. The impact on the person’s risk for 
depression will be the same whether this conflict is included in the life events or social 
predictors. When both are in the same model, this hypothetical event is effectively 
counted twice, which will lead to weaker relationships between both predictors and the 
outcome; similar overlap and partial mediation likely explains the other attenuated effect 
sizes observed in the multivariate results. Since they are likely the least biased, all 
betas (true regression coefficients) discussed in text are from the multivariate models. 
Marital termination, childhood and adulthood stressful life events were all 
associated with increased neuroticism – multivariate model beta, (95% Confidence 
Interval [CI], p-value): 0.23, (0.16 – 0.31, 7.84e-10); 0.15, (0.13 – 0.17, 2.35e-48); 0.19, 
(0.17 – 0.21, 7.18e-69), respectively; likelihood for MD – beta, (95% CI, p): 0.71, (0.51 – 
0.92, 6.41e-12); 0.37, (0.30 – 0.44, 3.27e-25); 0.27, (0.22 – 0.33, 1.46e-23); and 
comorbid MD+GAD  – beta, (95% CI, p): 0.67, (0.39 – 0.94, 1.93e-06); 0.42, (0.33 – 
0.50, 1.94e-20); 0.42, (0.34 – 0.49, 3.03e-28). Social support was associated with lower 
risk of MD and MD+GAD and with lower neuroticism – beta, (95% CI, p): -0.52, (-0.57 – 
-0.47, 7.89e-98); -0.59, (-0.66 – -0.51, 1.05e-48); -0.22, (-0.24 – -0.20, 2.28e-97). Each 
psychosocial predictor had a stronger association with risk of MD and MD+GAD than on 
neuroticism level, regardless of the direction of effect. Stressful life events in adulthood 
additionally had a stronger impact on risk of comorbid MD+GAD than on risk of MD – 
beta (95% CI): 0.42 (0.34 – 0.49) vs. (95% CI): 0.27 (0.22-0.33).
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Figure 1. CONVERGE Marital Termination. Left labels indicate outcome and model. 
Covariates include age and educational attainment. Multivariate model additionally 
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Figure 2. CONVERGE Social Support. Left labels indicate outcome and model. 
Covariates include age and educational attainment. Multivariate model additionally 
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Figure 3. CONVERGE Childhood Stressful Life Events. Left labels indicate outcome 
and model. Covariates include age and educational attainment. Multivariate model 
additionally includes marital termination, social support and adulthood stressful life 
events. 
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Left Figure 4. CONVERGE Adulthood Stressful Life Events. Left labels indicate 
outcome and model. Covariates include age and educational attainment. Multivariate 
model additionally includes marital termination, social support and childhood stressful 
life events. 
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Results from the psychosocial predictors in S4S can be found in Figures 5-8. 
Due to the presence of males and females as well as both East Asian and European 
ancestries, stratified analyses to test differences in the effect of psychosocial variables 
by sex or ancestry were possible. These stratified analyses are indicated by different 
colors in Figures 5-8. Note that EAS individuals were represented in the sample much 
less than EUR individuals in terms of sample size, so statistical power for the EAS 
analyses is reduced. Commentary about results is confined to the multivariate models, 
to decrease bias by adjusting for all predictors and covariates simultaneously. 
Relationship satisfaction had a small protective effect against depressive 
symptoms in the multivariate model – beta, (95% CI, p): -0.05 (-0.08 – -0.01, 0.01), 
which was also present in European individuals as a group, and males – beta, (95% CI, 
p):      -0.06 (-0.12 – -0.00, 0.04); -0.10 (-0.17 – -0.04, 2.90e-3), respectively, but not in 
East Asian individuals or females – beta, (95% CI, p): -0.03 (-0.20 – 0.14, 0.74); -0.02   
(-0.07 – 0.02, 0.34). The EAS effect estimate is comparable to the EUR (-0.03 vs. -
0.06), however, so this may be a limitation of sample size. For Neuroticism, while the 
trend was for relationship satisfaction to be protective, the effect was not significant in 
the multivariate model – overall beta, (95% CI, p): .-0.02 (-0.06 – 0.03, 0.47). 
Involvement in social activities was also found to be protective against 
depressive symptoms – beta, (95% CI, p): -0.14 (-0.18 – -0.10, 8.47e-14), with all 
subgroups enjoying approximately the same level of protection – beta, (95% CI, p) for 
EAS, EUR, male and female subgroups, respectively: -0.15 (-0.30 – -0.00, 0.05); -0.11 
(-0.17 – -0.06, 3.68e-5); -0.13 (-0.19 – -0.07, 3.74e-5); -0.14 (-0.19 – -0.10, 3.26e-10), 
though the precision of the EAS estimate is low. Social activities were also negatively 
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associated with neuroticism – overall beta, (95% CI, p): -0.10 (-0.14 – -0.06, 6.90e-6), in 
all subgroups but the EAS – beta, (95% CI, p) for EAS, EUR, male, and female, 
respectively: -0.15 (-0.31 – 0.01, 0.06); -0.09 (-0.15 – -0.03, 5.96e-3); -0.13 (-0.21 –       
-0.06, 4.6e-4); -0.08 (-0.14 – -0.03, 1.74e-3), again likely due to sample size. The 
influence of social activities was not notably different between depressive symptoms 
and neuroticism – betas: -0.14 vs. -0.10. 
Social support had a stronger negative association with depressive symptoms 
than the other protective factors – beta, (95% CI, p): -0.27 (-0.31 – -0.23, 1.31e-35). 
There were differences in this effect between subgroups, however. In EUR, the effect 
was quite strong – beta, (95% CI, p): -0.36 (-0.43 – -0.30, 4.33e-27), but there was not a 
significant association in EAS – beta, (95% CI, p): -0.07 (-0.23 – 0.09, 0.40). The 
magnitude of association was also greater in females, than in males – beta, (95% CI, p) 
for female and male subgroups, respectively: -0.31 (-0.36 – -0.26, 5.35e-32); -0.18        
(-0.25 – -0.11, 1.63e-6). Like relationship satisfaction, social support had a more modest 
negative association with neuroticism – overall beta, (95% CI, p): -0.13 (-0.17 – -0.08, 
5.9e-7), substantially smaller in magnitude than with depressive symptoms – betas:       
-0.13 vs. -0.27. The EAS and male groups again had a reduced effect of social support 
on neuroticism, not reaching significance – beta, (95% CI, p) for EAS and male 
subgroups, respectively: -0.01 (-0.18 – 0.16, 0.91); -0.04 (-0.13 – 0.05, 0.39), whereas 
the effects in EUR and females were stronger – beta, (95% CI, p) for EUR and female 
subgroups: -0.19 (-0.26 – -0.11, 9.52e-7); -0.16 (-0.22 – -0.10, 7.00e-8). 
Stressful life events were associated with increased depressive symptoms – beta 
(0.95% CI, p): 0.11 (0.09 – 0.12, 1.27e-37), and the magnitudes in the subgroups were 
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largely similar – beta (95% CI, p) for EAS, EUR, male and female subgroups, 
respectively: 0.12 (0.06 – 0.18, 1.25e-4); 0.09 (0.07 – 0.12, 3.50e-13); 0.09 (0.07 – 
0.12, 3.83e-11); 0.12 (0.10 – 0.14, 1.05e-28). Stressful life events were also associated 
with neuroticism – beta (95% CI, p): 0.05 (0.03 – 0.07, 1.72e-8), but less strongly than 
they were with depressive symptoms – betas: 0.05 vs. 0.11, respectively. The effect of 
stressful life events on neuroticism in EAS was not significant, but the other subgroup 
displayed similar levels of effect – beta, (95% CI, p) for EAS, EUR, male and female 
subgroups, respectively: 0.01 (-0.05 – 0.08, 0.65); 0.05 (0.02 – 0.08, 3.31e-4); 0.05 
(0.02 – 0.08, 3.06e-3); 0.06 (0.03 – 0.08, 9.94e-7).
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Figure 5. S4S Relationship Satisfaction. Left labels indicate outcome. Color indicates 
a subgroup of the sample, each with three consecutive models: univariate (on top), with 
covariates (next), and multivariate (bottom). Covariates include age, sex (when not 
stratified by sex), number of measurement occasions (when measured multiple times) 
and SES proxied by parental education level. Multivariate model additionally includes 
social activities, social support and stressful life events. 
S4S Relationship Satisfaction
Overall EAS EUR Male Female
Depressive Symptoms
Neuroticism
-0.275 -0.25 -0.225 -0.2 -0.175 -0.15 -0.125 -0.1 -0.075 -0.05 -0.025 0
Regression Coefficient
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Figure 6. S4S Social Activities. Left labels indicate outcome. Color indicates a 
subgroup of the sample, each with three consecutive models: univariate (on top), with 
covariates (next), and multivariate (bottom). Covariates include age, sex (when not 
stratified by sex), number of measurement occasions (when measured multiple times) 
and SES proxied by parental education level. Multivariate model additionally includes 
relationship satisfaction, social support and stressful life events. 
S4S Social Activities
Overall EAS EUR Male Female
Depressive Symptoms
Neuroticism
-0.325 -0.3 -0.275 -0.225 -0.2 -0.175 -0.125 -0.1 -0.075 -0.025 0
Regression Coefficient
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Figure 7. S4S Social Support. Left labels indicate outcome. Color indicates a 
subgroup of the sample, each with three consecutive models: univariate (on top), with 
covariates (next), and multivariate (bottom). Covariates include age, sex (when not 
stratified by sex), number of measurement occasions (when measured multiple times) 
and SES proxied by parental education level. Multivariate model additionally includes 
relationship satisfaction, social activities and stressful life events. 
S4S Social Support
Overall EAS EUR Male Female
Depressive Symptoms
Neuroticism
-0.425 -0.375 -0.325 -0.275 -0.225 -0.175 -0.125 -0.075 -0.0250
Regression Coefficient
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Figure 8. S4S Stressful Life Events. Left labels indicate outcome. Color indicates a 
subgroup of the sample, each with three consecutive models: univariate (on top), with 
covariates (next), and multivariate (bottom). Covariates include age, sex (when not 
stratified by sex), number of measurement occasions (when measured multiple times) 
and SES proxied by parental education level. Multivariate model additionally includes 
relationship satisfaction, social activities and social support. 
S4S Stressful Life Events
Overall EAS EUR Male Female
Depressive Symptoms
Neuroticism
0 0.025 0.05 0.075 0.1 0.125 0.15 0.175
Regression Coefficient
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III.  Discussion: 
As expected, the majority of the psychosocial factors displayed strong positive or 
negative associations with MD, MD+GAD, neuroticism and depressive symptoms 
outcomes. There were some notable differences between samples and subgroups, 
however. CONVERGE, likely in part due to the large sample size and detailed 
assessments, showed precise association estimates for the predictors, which were in 
every case of higher magnitude for the psychiatric outcomes of MD and MD+GAD than 
for neuroticism levels. This is consistent with the past biometrical literature suggesting 
that neuroticism constitutes a portion of the variance in risk of MD and GAD (51), 
showing associations with the same risk factors as the disorder outcomes do.  
In S4S, the estimates were less precise, but analyses stratified by sex and 
ancestry were possible. Relationship satisfaction displayed no significant association 
with neuroticism, but did have a small protective effect against depressive symptoms, 
which is intuitive, given the preponderance of loneliness in many depressive 
presentations. Interestingly, the protective effect of relationship satisfaction on 
depressive symptoms was stronger in males than females (non-significant in females). 
This seems to corroborate work on sex differences in the effect of marriage as a 
protective factor – reduced risk of depression was found for married men, but not 
married women (122). Involvement in social activities had a similarly small protective 
effect against both depressive symptoms and neuroticism, and estimates were similar 
across subgroups, except for low precision in EAS.  
Social support, however, had a stronger negative association with depressive 
symptoms, and a modest negative association with neuroticism. It is notable that the 
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effects were heightened for the subgroups of EUR and females for both outcomes (EAS 
effects for both outcomes were estimated lower and were non-significant, and effects in 
males were lower for depressive symptoms and non-significant for neuroticism). This 
extra protective effect of social support for females has been demonstrated in regards to 
major depression as well (123). As discussed in the methods section of this chapter, 
there is likely to be causal action in both directions between social support and the so-
called outcomes of depressive symptoms and neuroticism. Internalizing presentations 
and neurotic personality features displayed by an individual can be difficult for friends 
and family, and may lead to erosion of social relationships and support networks. 
Conversely, strong support from loved ones and friends can have an ameliorative effect 
on depressive symptoms and neuroticism. The presence of the relationship (stronger in 
females than males) is the relevant finding from this evidence, rather than the 
directionality. 
Finally, stressful life events were associated with increased depressive 
symptoms and neuroticism, though again the effect was stronger for depressive 
symptoms, and in this case there was little evidence of subgroup differences. 
Overall, these results suggest that neuroticism is associated with the same set of 
psychosocial correlates as MD and GAD. The S4S results indicate that there is 
evidence of sex differences in the association of psychosocial factors with depressive 
symptoms and (to a lesser degree) neuroticism. The variables that correspond with the 
quality of close personal relationships (romantic or platonic), such as relationship 
satisfaction and social support, seem to have differential impact on these outcomes. 
Relationship satisfaction shows a stronger negative relationship with depressive 
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symptoms for males, whereas social support is more strongly associated with lower 
depressive symptoms and neuroticism in females. Social support may be more strongly 
associated with protection against depressive symptoms and neuroticism for individuals 
of European ancestry than East Asian ancestry in the S4S sample. Note that the effect 
of social support on neuroticism in CONVERGE was very pronounced, however so the 
non-significance of the associations in EAS group may be an artifact of the small 
sample size. The two samples differ substantially, with CONVERGE being ascertained 
for major depression and S4S being recruited from college students, among other 
differences. This leads to different levels of endorsement of psychosocial risk factors, 
possibly indicating some confounding effects of sample differences – for instance, the 
most common level of social support endorsed in CONVERGE was moderate, whereas 
the most common level endorsed in S4S was the highest level of support. There is not 
sufficient information available in this project to disentangle these potential sources of 
bias, but the overall consistency of all risk factors acting in the expected direction 
(significantly so in most tests), is somewhat encouraging.









I.  Methods:  
Samples: All datasets were used in this set of analyses, including CONVERGE, 
MGS, and S4S. CONVERGE comprises information from Han Chinese females of ages 
30-60. MGS comprises information from European individuals from ages 18-90.  There 
are 1355 females and 1257 males used in this analysis from the MGS sample. S4S 
comprises information from individuals of multiple ancestries from ages 18-32. There 
are 3016 individuals of European ancestry (EUR), 557 individuals of East Asian 
ancestry (EAS), 1471 males, and 2069 females used in this analysis from the S4S 
sample cohorts 1-3, which were the subset included in these analyses. S4S cohort 1 
had responded to 3 years of survey follow-up, cohort 2 had responded to 2 years of 
survey follow-up, and cohort 3 had responded to 1 year of survey follow-up when data 
was assembled for these analyses. Notably, imputation for all of these samples had 
been carried out by unrelated efforts prior to the beginning of this project, so QC 
focused primarily on downstream efforts to ensure all interpreted results were high 
quality. 
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Variables: Outcomes in CONVERGE include BFI neuroticism (110), which was 
standardized, MD status, and a dichotomous outcome of MD+GAD comorbidity versus 
MD controls – a ‘case-control’ test of MD+GAD status. Outcomes in MGS include GAD 
status, MD status, a similar MD+GAD comorbid outcome, and BFI neuroticism score 
(110). Outcomes in S4S include an abbreviated 3-item BFI neuroticism score (110), and 
a sum score of 4 SCL-90 depressive symptoms (114), both of which were standardized.  
Covariates for CONVERGE, MGS and S4S were used to adjust for the effects of 
demographic factors, when appropriate. Age at assessment was included in all 
analyses, as well as sex (except in CONVERGE, as that sample is all female). 
Analyses: Genetic association tests, with one exception, were conducted using 
BOLT-LMM (124), a linear mixed model method that achieves increased power over 
most other mixed model association tools while retaining the ability to account for 
population stratification and cryptic relatedness. The association test for depressive 
symptoms in the EAS subgroup of S4S was conducted in PLINK (125), with adjustment 
for 10 ancestry principal components in addition to the other covariates, since 
association analysis failed in BOLT-LMM due to the generation of an invalid (too low) 
heritability estimate, likely as a result of the small sample size of this subgroup. PLINK 
is a reliable analysis tool, and has relatively good power in a range of circumstances, 
though not as powerful as BOLT-LMM. That is to say, PLINK would be a tolerable 
alternative to all association analyses, but where BOLT-LMM’s assumptions are met 
and heritability estimation is possible, it is likely to provide more accurate results, with 
more evenly controlled Type 1 error. Mixed models, generally speaking, are 
combinations of fixed and random variables that partition the variance of an outcome 
	   54	  
between them.  A fixed effect is a variable whose impact is constant across individuals, 
such as the population effect on a trait of having one non-reference allele instead of the 
reference allele at a particular locus. A random effect is a variable that may have 
different impact for each individual, such as the overall effect of the polygenic 
background of a given person. With respect to genetic association analysis, mixed 
models generally refer to the inclusion of a matrix of genotypic relatedness as a random 
effect in the regression of the phenotype on the fixed effect of genotype at each locus. 
Mixed models have been used to prevent bias in the estimation of genetic effects due to 
selection in animal genetics (126), and more recently to control for both population and 
family structure in human genetics (127).  
BOLT-LMM is a good choice among mixed model methods due in part to its 
efficiency; its direct use of genotypes to compute the random-effect variance 
components saves time, scaling linearly with both sample size and number of markers 
(compared to quadratic scaling with regards to one of the two variables implemented in 
other mixed model methods), and it is highly optimized for savings in both 
computational time and memory usage (124). It also has the capability to calculate 
random effects drawn from Gaussian mixture priors, as opposed to the ‘infinitesimal’ 
model (128) implicit in standard linear mixed models, when the circumstances suggest 
doing so will increase power. The infinitesimal model was predicted to be the highest 
powered in all analyses in this project, however. As suggested by the BOLT-LMM 
documentation (124), imputed dosage data were hard-called into binary PLINK 
genotypes, with variants with high-confidence genotype probability (the most likely 
genotype call had to be a probability of 0.9 or higher) included in the hard-called 
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genotype subset.  SNPs were filtered in the process of association testing for no greater 
than 10% missingness among the sample individuals. These permissive filtering 
thresholds were intended to maximize the number of SNPs included in the mixed 
model. After associations were computed, results were further filtered so that all 
variants included in figures displaying association peaks, and interpreted in the text, had 
MAF >1%, and imputation information >0.5. Manhattan and quantile-quantile (q-q) plots 
were generated using the qqman package in R (129). Genomic inflation factors were 
calculated using the GenABEL package in R (130). LocusZoom plots were also 
produced for significant loci (131). 
After association analyses, integration of the variant results by genomic intervals 
was performed with Multi-marker Analysis of Genomic Annotation, or MAGMA (132). 
MAGMA is a flexible gene and gene-set based analysis program that efficiently 
implements a number of analytic approaches to estimating the level of association 
between a specified region or regions and an outcome. Adjustment for multiple testing 
was computed using the Bonferroni correction (133) for the number of intervals included 
in each outcome and sample, to ensure a family-wise error rate of 0.05. To preserve the 
benefits of BOLT-LMM in these interval-based associations, first the p-value based 
method of mean variant association was used in MAGMA, which is comparable to other 
gene-based methods; this is broadly a test of the enrichment of association in variants 
in a given genomic region, which may be driven in part by LD. These results are then 
compared with the regression model using genotypes directly with MAGMA, though this 
neither uses a mixed model approach nor post-imputation dosage data, so is likely to 
have lower statistical power. It is, however, a very specific test, with a well-controlled 
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Type 1 error rate (132). To avoid theoretically-based assumptions about relevant 
genetic effects primarily stemming from e.g. coding regions, a comprehensive list of 
regions was pulled from GENCODE (134), 58,977 in all, which in addition to traditional 
primary protein-coding transcripts includes protein-coding genes with alternatively-
spliced variants, non-coding loci, pseudogenes, as well as intergenic regions between 
them (to include any potentially unmapped regulatory sites of action). 
 
II.  Results:  
The association results only resulted in genome-wide significant loci, with a p-
value less than 5 × 10-8 (135), in a few of the outcomes tested. A subset of these loci 
evinced additional supportive signals consistent with a true genetic effect on a 
background haplotype. Manhattan and q-q plots were generated for each test, with 
LocusZoom (131) plots for all regions attaining genome-wide significance, using the 
appropriate reference panel (ASN or EUR) from 1000 Genomes (136) to determine 
whether these appear plausible (Figures 9-53). 
For CONVERGE, the MD GWAS was unique in that the CONVERGE group had 
already published results (93), so to some extent the test was to validate the 
methodology, though slight differences including using BOLT-LMM as opposed to 
another mixed model technique, and including age as a covariate, did result in 
somewhat altered associations. The q-q plot displayed moderate inflation at the tail 
(Figure 10), and the test had a genomic inflation factor (λ) of 1.147, which when scaled 
to a theoretical test for 1000 cases and 1000 controls (λ1000) was 1.028. The two 
published loci on chromosome 10 show strong peaks in the Manhattan plot (Figure 9), 
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though only one, the locus in the phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase (LHPP) gene (rs35936514, p=3.2e-08), reaches 
significance in this test due to the different analytic approach (Figure 11). The LHPP 
gene hydrolyzes a range of phosphate molecules, and is expressed in the brain. The 
other locus from the original publication did reach significance without the adjustment 
for the age covariate: rs12415800 in the sirtuin1 or SIRT1 gene, p=3.1e-08 in the 
unadjusted association test versus 8.4e-08 in the adjusted test; rs35936514, the top 
variant in the LHPP gene, had a p=7.0e-09 in the unadjusted test vs. 3.2e-08 in the 
adjusted test (unadjusted results not shown). The second variant reaching significance 
in the present analysis on chromosome 19 in the perilipin 4 (PLIN4) gene, (rs7257142, 
p=1.9e-09), was not supported by nearby variants of suggestive significance, and is not 
present in publically-available East Asian LD reference panels (Figure 12). It may have 
low LD, be a spurious signal or be a speciously imputed variant. The PLIN4 gene may 
be related to adipocyte functioning, and is expressed during adipocyte differentiation, 
which would appear to be distal to the central pathology in MD. The results for comorbid 
MD+GAD in CONVERGE were less strong, which was as expected given the reduced 
number of cases in this analysis. There were no loci reaching significance (Figure 13). 
The q-q plot (Figure 14) suggests modest genomic inflation overall, and signal in the 
tail, with λ of 1.047 and λ1000 of 1.023. For CONVERGE Neuroticism, there were also no 
significant loci (Figure 15). This is likely due to insufficient signal to detect modest 
effects in this sample, as the q-q plot suggests perhaps the mixed model, in correcting 
for relatedness and population structure, deflated the strongest Neuroticism 
associations (Figure 16), though λ was 1.097 and λ1000 was 1.020. 
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Figure 9. MD BOLT-LMM Results in CONVERGE. Manhattan plot displaying filtered 
adjusted association results, arranged by physical position.
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Figure 10. MD q-q Plot in CONVERGE. Quantile-quantile plot visualizing observed 
versus expected association strength.
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Figure 11. CONVERGE MD Chromosome 10 Locus. LocusZoom plot displaying 
strongest associated variant with coloring to indicate LD relationships with other nearby 
variants. Grey points indicate variants missing LD information with respect to the 
strongest variant. Genes in the region displayed for reference.
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Figure 12. CONVERGE MD Chromosome 19 Locus. LocusZoom plot displaying 
strongest associated variant with coloring to indicate LD relationships with other nearby 
variants. Grey points indicate variants missing LD information with respect to the 
strongest variant. Genes in the region displayed for reference.
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Figure 13. MD+GAD BOLT-LMM Results in CONVERGE. Manhattan plot displaying 
filtered adjusted association results, arranged by physical position.
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Figure 14. MD+GAD q-q Plot in CONVERGE. Quantile-quantile plot visualizing 
observed versus expected association strength.
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Figure 15. Neuroticism BOLT-LMM Results in CONVERGE. Manhattan plot 
displaying filtered adjusted association results, arranged by physical position. 
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Figure 16. Neuroticism q-q Plot in CONVERGE. Quantile-quantile plot visualizing 
observed versus expected association strength.
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Association results for the MGS sample were mostly, but not completely, null. 
MD in the MGS sample displayed no significant loci (Figure 17). Any potential signal did 
not survive correction (Figure 18), though overall there was some inflation, with a λ 
estimate of 1.147 and estimate of and λ1000 of 1.149. 
There were also no significant loci for the comorbid MD+GAD outcome in MGS 
(Figure 19). Genomic inflation, in contrast to the MD outcome in MGS, appeared 
minimal with a λ and λ1000 estimate of 1 (the minimum in GenABEL), with signal at the 
high end balanced by deflation in the lower p-values (Figure 20). 
The results for GAD in MGS were somewhat stronger, with two loci reaching 
significance (Figure 21). Genomic inflation appeared minimal overall with a λ and λ1000 
estimate of 1(the minimum in GenABEL), with signal at the high end balanced by 
deflation in the lower p-values (Figure 22). Both these loci have some supporting 
signals, though not enough to declare them genuine associations with complete 
certainty. The first locus (most significant variant: rs117420048, p=1.7e-09), in the intron 
of LINC00824, a long non-coding RNA (Figure 23), has the more supportive pattern, 
with a few strong highly-correlated variants near the top hit, and suggestive variants in 
weaker LD further away. The other locus on chromosome 13 (Figure 24), around 
LINC00348, another long non-coding RNA (most significant variant: rs146220192, 
p=4.6e-08), has a few supporting signals of suggestive significance, but only modest LD 
with the top variant. 
The MGS associations for Neuroticism were, like CONVERGE, non-significant 
(Figure 25). Signals appeared to be over-corrected in the tail, similar to the pattern of 
neuroticism in CONVERGE (Figure 26). λ was 1.047 and λ1000 1.101.
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Figure 17. MD BOLT-LMM Results in MGS. Manhattan plot displaying filtered 
adjusted association results, arranged by physical position.
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Figure 18. MD q-q Plot in MGS. Quantile-quantile plot visualizing observed versus 
expected association strength.
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Figure 19. MD+GAD BOLT-LMM Results in MGS. Manhattan plot displaying filtered 
adjusted association results, arranged by physical position.
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Figure 20. MD+GAD q-q Plot in MGS. Quantile-quantile plot visualizing observed 
versus expected association strength.
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Figure 21. GAD BOLT-LMM Results in MGS. Manhattan plot displaying filtered 
adjusted association results, arranged by physical position.
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Figure 22. GAD q-q Plot in MGS. Quantile-quantile plot visualizing observed versus 
expected association strength.
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Figure 23. MGS GAD Chromosome 8. LocusZoom plot displaying strongest 
associated variant with coloring to indicate LD relationships with other nearby variants. 
Grey points indicate variants missing LD information with respect to the strongest 
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Figure 24. MGS GAD Chromosome 13 Locus. LocusZoom plot displaying strongest 
associated variant with coloring to indicate LD relationships with other nearby variants. 
Grey points indicate variants missing LD information with respect to the strongest 
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Figure 25. Neuroticism BOLT-LMM Results in MGS. Manhattan plot displaying 
filtered adjusted association results, arranged by physical position.
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Figure 26. Neuroticism q-q Plot in MGS. Quantile-quantile plot visualizing observed 
versus expected association strength.
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The results for the S4S sample included the fewest significant loci, with only one 
genomewide significant finding. The small sample size in the EAS group, and the 
reduced contrast between high and low levels of depressive symptoms and neuroticism 
in this healthy college-age population likely contributed to lack of power. Depressive 
symptoms results in the EAS subgroup had no loci reach significance (Figure 27). The 
q-q plot indicates that there may be uneven correction of the association results by 
PLINK using principal components (Figure 28), in addition to PLINK’s reduced power 
compared with BOLT-LMM. Genomic inflation, however, was modest with a λ estimate 
of 1.004 and λ1000 estimate of 1.044. Depressive symptoms results in the EUR subgroup 
were somewhat stronger, but again none reached significance (Figure 29). The q-q plot 
suggests good correction (Figure 30), which is corroborated by the λ value of 1.047 and 
λ1000 of 1.021, but power appears to have been insufficient. Neuroticism results were 
quite weak in the EAS subgroup (Figure 31). As with Neuroticism results in other 
samples, the q-q plot suggests overcorrection by the mixed model approach (Figure 
32), which is consistent with the λ and λ1000 estimate of 1 (the minimum in GenABEL). 
Neuroticism results in the EUR subgroup presented the only significant locus from S4S 
(Figure 33), on chromosome 4 (most significant variant: rs113888384, p=1.4e-08). This 
is notable due to the same pattern of overcorrection seen in the other Neuroticism 
association tests being evident in the q-q plot (Figure 34), though the λ estimate of 
1.047 and λ1000 estimate of 1.021 suggest some signal. The association peak is in the 
collapsin response mediator protein 1 (CRMP1) gene (Figure 35). The gene is 
expressed exclusively in the nervous system, and is thought to be involved in neural 
development.
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Figure 27. Depressive Symptoms PLINK Results in S4S (EAS). Manhattan plot 
displaying filtered adjusted association results, arranged by physical position.
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Figure 28. Depressive Symptoms q-q Plot in S4S (EAS). Quantile-quantile plot 
visualizing observed versus expected association strength.
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Figure 29. Depressive Symptoms BOLT-LMM Results in S4S (EUR). Manhattan plot 
displaying filtered adjusted association results, arranged by physical position. 
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Figure 30. Depressive Symptoms q-q Plot in S4S (EUR). Quantile-quantile plot 
visualizing observed versus expected association strength.
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Figure 31. Neuroticism BOLT-LMM Results in S4S (EAS). Manhattan plot displaying 
filtered adjusted association results, arranged by physical position. 
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Figure 32. Neuroticism q-q Plot in S4S (EAS). Quantile-quantile plot visualizing 
observed versus expected association strength.
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Figure 33. Neuroticism BOLT-LMM Results in S4S (EUR). Manhattan plot displaying 
filtered adjusted association results, arranged by physical position. 
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Figure 34. Neuroticism q-q Plot in S4S (EUR). Quantile-quantile plot visualizing 
observed versus expected association strength.
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Figure 35. S4S (EUR) Neuroticism Chromosome 4 Locus. LocusZoom plot 
displaying strongest associated variant with coloring to indicate LD relationships with 
other nearby variants. Grey points indicate variants missing LD information with respect 
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Interval-based results from MAGMA provide a single test statistic for all variants 
within a particular genomic region, allowing for biologically-relevant aggregation of 
signal. Intervals meeting genome-wide significance in the aggregation of BOLT-LMM 
association p-values are displayed in Tables 7-11, along with their p-values from the 
genotypic regression, a conservative test, due to low Type 1 error rate.  
In CONVERGE, there were significant intervals in all outcomes. 17 intervals 
reached significance for MD in the p-value aggregation, with 8 reaching nominal 
significance in the conservative genotype regression, and two reaching genome-wide 
significance in both tests, an intergenic region, which does contain a number of potential 
regulatory regions, and a CpG island (genotypic regression p-value = 4.35e-07), and the 
HECT and RLD domain containing E3 ubiquitin protein ligase 4 (HERC4) gene 
(genotypic regression p-value = 4.95e-07), which is related to ubiquitin and is brain-
expressed (Table 7).  
12 intervals reached significance in the p-value aggregation analysis for 
MD+GAD in CONVERGE, with 2 reaching nominal significance in the genotypic 
regression test, CDKN2A-AS1 and SOX9-AS1 (genotypic regression p-values = 2.5e-04 
and 0.04, respectively), both long non-coding RNA (Table 8).  
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Table 7. Significant Gene-based MAGMA Results for MD in CONVERGE 




KIAA0040  5.8167e-09 0.002968 
SYT14  2.2852e-08 0.047366 
HHAT 8.2152e-08 0.38987 
ETV5-AS1 3.814e-07 0.00035098 
ADH4 2.7816e-08 0.45402 
SEMA5A 5.212e-07 0.18465 
RANP1 1.2247e-08 0.51969 
CTC-756D1.2 2.2481e-07 0.39747 
DNAJC12 2.4477e-09 3.7593e-05 
intergenic_chr10_00536* 1.096e-08 4.3519e-07 
SIRT1 2.6752e-08 0.00020047 
HERC4* 1.6725e-08 4.9483e-07 
RP11-474D14.2 1.145e-07 1.1102e-06 
ABCC8 3.0105e-124 0.35324 
RP11-72M17.1 3.7146e-07 0.3233 
RP11-580I1.2 2.5724e-72 0.78932 
HIC2 3.4965e-53 0.59541 
77,543 intervals were included in this test, corresponding to a Bonferroni significance 
threshold of 6.4e-07 for a family-wise error rate of 5%. 
Bold results are at least nominally significant in both tests. 
* indicates genomic region met Bonferroni significance threshold in both tests. 
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SYT14 2.4821e-08 0.14522 
HHAT 6.1425e-08 0.37532 
RANP1 2.5215e-09 0.6582 
CDKN2A-AS1 3.313e-07 0.00024967 
ABCC8 3.8574e-118 0.30306 
OR4C11 6.6884e-10 0.071712 
RP11-490P13.2 4.7155e-09 0.53378 
intergenic_chr13_00386 9.9138e-08 0.12516 
SQSTM1P1 3.3201e-08 0.083037 
RP11-580I1.2 2.3201e-89 0.76914 
SOX9-AS1 6.2512e-07 0.040681 
HIC2 6.6655e-42 0.59986 
77,543 intervals were included in this test, corresponding to a Bonferroni significance 
threshold of 6.4e-07 for a family-wise error rate of 5%. 
Bold results are at least nominally significant in both tests. 
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For neuroticism in CONVERGE, 9 results were significant in the p-value 
aggregation, and 2 reached nominal significance in the genotypic regression test as 
well, POLR1C and POLH (genotypic regression p-values = 0.03 and 0.02, respectively), 
polymerase subunit genes (Table 9).  
In MGS, only the GAD outcome displayed Bonferonni-significant findings in the 
p-value aggregation test, which were also nominally significant in the genotype 
regression test (Table 10). LINC01346 and RP11-1144P22.1 are long non-coding RNA, 
while KLB is involved in the synthesis of bile acid, and is expressed to some extent in 
the brain.  
Finally, in S4S, only neuroticism in the EAS subgroup showed significant findings 
in the p-value aggregation test, but none reached significance in the genotypic 
regression (Table 11).
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ADGRV1 3.233e-07 0.1948 
RANP1 2.7614e-14 0.071325 
POLR1C 3.6846e-07 0.029229 
POLH 4.8682e-08 0.022696 
RP3-337H4.8  1.4238e-07 0.0041096 
ABCC8 1.4917e-154 0.44783 
IGHV1-12 1.1472e-08 0.54778 
RP11-580I1.2  2.3842e-80 0.36532 
HIC2 6.6655e-42 0.85815 
77,543 intervals were included in this test, corresponding to a Bonferroni significance 
threshold of 6.4e-07 for a family-wise error rate of 5%. 
Bold results are at least nominally significant in both tests. 
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LINC01346 4.8836e-07 5.6434e-05 
KLB 6.4351e-07 0.00042416 
RP11-1144P22.1 1.5175e-07 0.00034395 
73,602 intervals were included in this test, corresponding to a Bonferroni significance 
threshold of 6.8e-07 for a family-wise error rate of 5%. 
Bold results are at least nominally significant in both tests. 
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CHIA 3.3799e-28 0.67696 
SYT6 1.7558e-13 0.70484 
GNB1L 1.6089e-11 0.36906 
58,952 intervals were included in this test, corresponding to a Bonferroni significance 
threshold of 8.5e-07 for a family-wise error rate of 5%.
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III.  Discussion: 
The search for specific genetic loci with a probable impact on MD, GAD, and 
neuroticism is not an easy one. The vast majority of signals for complex traits have 
small effect sizes, as has been well-established in the GWAS literature (137). The 
outcomes studied here also have moderate heritability, suggesting that a substantial 
portion of their etiologies are environmental in origin. Nevertheless, there was some 
degree of promise in the findings, with 10 loci that may contain variants with some role 
in MD, GAD or neuroticism, and a number of genes whose variants, in aggregate, 
suggest a relationship with one of these outcomes as well. 
Perhaps the most expected finding was the significance of previously published 
significant variants from MD in CONVERGE. Only one of the two loci previously found 
on chromosome 10 was significant in the covariate-adjusted analysis, however. The 
rs35936514 variant, in the LHPP gene, which despite having a function in phosphate 
processing (a process ostensibly somewhat distal to the etiology of MD), is expressed in 
the brain, and based upon follow-up work in the literature, the variant appears to have 
some effects on activity in certain brain regions (138). The other previously published 
variant, in the SIRT1 gene, has a clear peak just before LHPP on chromosome 10 as 
(Figure 9), and indeed was significant when the association test was not adjusted for 
the age covariate. The only novel variant significant in the MD association analysis was 
rs7257142, in the PLIN4 gene, on chromosome 19. The variant is not supported by 
other nearby suggestive signals, though LD is low in East Asian populations in genomic 
region around this locus. PLIN4 is involved in adipocyte functioning, which is of unclear 
relevance to MD etiology; replication and further research will be needed to determine 
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whether the gene is likely to be a true risk locus for MD, and what role it may play in MD 
physiology. 
MGS, despite the smaller sample size than CONVERGE, did produce a pair of 
significant loci as well. Only the GAD outcome produced significant results in this 
sample. The most encouraging peak was found for rs117420048, in the intron of 
LINC00824, a long non-coding RNA on chromosome 8. The other significant variant 
was rs146220192, in LINC00348, another long non-coding RNA on chromosome 13. 
The LD patterns of supporting signals in these loci are not as strong as the 
chromosome 10 CONVERGE MD locus, and the potential functional roles of long non-
coding RNA as a class are highly varied, with established functions still missing for 
many of them (139). Thus, the etiological significance of these loci is unclear. 
In S4S, only one locus reached significance, which was for neuroticism in the 
EUR subgroup. The top variant was rs113888384, in the CRMP1 gene on chromosome 
4, which is involved in the collapse of the growth cone in neural development. As this is 
believed to be an important part of axon guidance in the brain, the relevance to 
neuroticism as a dispositional trait corresponding to liability to internalizing 
psychopathology is clear; indeed, CRMP1 has been implicated in connection with 
schizophrenia and major depression (140) 
In comparing results to past work, such as the published variants listed in Table 
5, the majority did not replicate. This is likely due more to the limited sample size of the 
present analysis than high rates of false positives in past published work, but further 
analyses will be required to determine which results are true positives. A total of four 
variants from a large meta-analysis (95) did replicate in at least one test, however. The 
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neuroticism variants of rs2150472 and rs12903563 replicated at suggestive significance 
in the CONVERGE neuroticism analysis (p-values of 4.7 × 10-3 and 1.4 × 10-3, 
respectively) which, it is worth noting, would constitute a transethnic replication from 
European to East Asian ancestries, if true. The neuroticism variant of rs2572431 
replicated at suggestive significance in the MGS neuroticism analysis (p = 4.9 × 10-3), 
and, surprisingly, the variant rs7973260 associated with depressive symptoms 
replicated with suggestive significance in the S4S EAS subgroup (p = 8.9 × 10-3), which 
is both East Asian in ancestry and of small sample size. These consistencies with past 
work are somewhat encouraging, as one would not expect any variants to replicate in 
samples the size of MGS and S4S, but the weak p-values indicate that these ostensible 
replications may simply be due to chance variation.   
Interval-based results from MAGMA are similarly mixed, with some promising 
and some probably spuriously significant results. When the initial BOLT-LMM follow-up 
method of aggregating p-values returned a significant result after multiple testing 
correction, validation by looking at the regression-based p-value provides a reasonable 
check of whether the result is likely to be a true positive. The most significant intervals 
were found for CONVERGE MD, which is unsurprising given that this association 
analysis was the one with the highest power in the whole project. 8 of these regions 
retained nominal significance in the regression-based test. Some of these were obscure 
in function: KIAA0040 is a gene encoding an uncharacterized protein and ETV5-AS1 is 
a long non-coding RNA. Others were seemingly more related to MD, such as SYT14, a 
gene involved in synaptic transmission. Notably, there was a collection of significant 
intervals in the same genomic region of chromosome 10, which have some overlap: 
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DNAJC12 is a protein in the heat shock family which is highly brain-expressed, an 
intergenic region in the area containing regulatory markers but no transcripts, HERC4 is 
a brain-expressed ubiquitin ligase, a catalyst for certain reactions involving ubiquitin; 
RP11-474D14.2 is a pseudogene in an intron of HERC4, and SIRT1, of course, is the 
locus which was genome-wide significant in the previously published CONVERGE 
paper (93), but just failed to meet the significance threshold in the covariate-adjusted 
association analysis. Two of these, the intergenic region in this area, and HERC4, 
actually met genome-wide significance in both interval-based tests, suggesting this 
region likely has some role in MD physiology.  
Tests in the other outcomes in CONVERGE produced a couple of significant 
intervals each. For the MD+GAD outcome, two long non-coding RNAs were at least 
nominally significant in both MAGMA test methods: CDKN2A-AS1 and SOX9-AS1. In 
CONVERGE neuroticism, two genes involved in the production of polymerase units 
came up, POLR1C and POLH. These are genes whose role in psychopathology is 
difficult to discern; it’s unclear what the role of these particular long non-coding RNA 
may be, given the highly variable and poorly understood functions of many long non-
coding RNA, as mentioned above (139). Conversely, mutations in polymerase enzymes 
are known to be involved in certain Mendelian conditions, such as Treacher Collins 
syndrome (141) and Xeroderma Pigmentosum (142), but no evidence for a relationship 
with personality has been found previously.  
Of the non-CONVERGE interval-based results, only the GAD outcome in MGS 
produced any significant regions, though all three met nominal significance thresholds in 
both MAGMA tests. All seem to lack obvious connection to GAD, with two more long 
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non-coding RNA in LINC01346 and RP11-1144P22.1, and KLB, a gene involved in the 
synthesis of bile acid expressed in a variety of tissues including the brain.  
The minimal overlap between the variant-based and interval-based tests is 
perhaps unexpected, though the goals of the two methods are somewhat different, if 
related. The variant-based tests explore the statistical effect of specific polymorphisms 
on the outcome of interest. The interval-based tests examine the degree to which 
variation in an entire genomic region is related to the outcome. Instances where there 
are polymorphisms of (relatively) high impact in a tightly-defined area, such as an exon 
may produce an individually-significant variant. Alternatively, the density of associated 
polymorphisms with sub-threshold effects in the region may suffice to produce a 
significant interval even without any variants of genome-wise significance. Of course, a 
sufficiently impactful area of the genome may produce both results – the SIRT1 area on 
chromosome 10 produced a significant peak in the CONVERGE MD association test 
without age adjustment, plus multiple significant intervals in the same vicinity (including 
the SIRT1 gene itself), two with genome-wide significance in both interval-based tests. 
The specific genetic loci identified in this chapter are initial efforts in detailing the 
modest proportion of variance in MD, GAD and neuroticism attributable to genetic 
factors in biometrical studies (81, 84, 87). Some are truly promising, such as strong 
findings in CONVERGE (some of which have already been included in prior 
manuscripts), while others are potentially artefactual. Due primarily to the limited sample 
size in this analysis, few of the results are strong and unambiguous. It is wise, therefore, 
to not rely on the ultimate truth of any of these findings until they have been 
convincingly replicated in other future studies. 




Chapter 4: Estimation of genetic variance, correlation, and cross-prediction in 




I.  Methods: 
Samples: As with Chapter 3, all datasets were used in at least some of this set 
of analyses, including CONVERGE, MGS, and S4S. CONVERGE comprises 
information from Han Chinese females of ages 30-60. MGS comprises information from 
European individuals from ages 18-90.  There are 1355 females and 1257 males used 
in this analysis from the MGS sample. S4S comprises information from individuals of 
multiple ancestries from ages 18-32. There are 3016 individuals of European ancestry 
(EUR), 557 individuals of East Asian ancestry (EAS), 1471 males, and 2069 females 
used in this analysis from the S4S sample cohorts 1-3, which were the subset included 
in these analyses. S4S cohort 1 had responded to 3 years of survey follow-up, cohort 2 
had responded to 2 years of survey follow-up, and cohort 3 had responded to 1 year of 
survey follow-up when data was assembled for these analyses. 
Variables: Most of the analyses in this chapter use genetic information to 
estimate overall quantitative values related to the main outcome phenotypes, singly or 
in pairs. These outcomes include MD, GAD, comorbid MD+GAD, neuroticism, and 
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depressive symptoms. For polygenic scoring, two sets of external summary statistics 
were used for the discovery phenotypes of depressive symptoms and neuroticism (95). 
Analyses: Estimation of univariate genetic variance was undertaken with GCTA 
(99), and LDSC (100). GCTA is a method that uses a genetic relatedness matrix, a 
representation of overall identical-by-state (IBS) relatedness (whether a pair of 
individuals has zero, one, or two alleles at a particular polymorphic genomic locus in 
common), between each pair of individuals in the sample. LDSC uses linkage 
disequilibrium relationships between a variant and nearby regions to calculate a single 
quantitative index of how much LD a variant has; the ‘LD score’. This LD score is 
compared with the level of association the locus has with the outcome, with respect to 
the intuition that, for a polygenic trait, a locus with more LD should have a larger effect. 
The differential between this expected relationship and the observed pattern of 
associations is used to estimate genetic variance. Both methods were used in order to 
provide convergent evidence of the precise heritability estimate for each outcome, and 
also due to differences in implementation potentially allowing one to succeed in an edge 
case where the other fails. 
For bivariate estimation of genetic correlation, GCTA (143) and LDSC (144) were 
used once more. GCTA uses a bivariate linear mixed model, where polygenic effects on 
both outcomes are used for individuals to estimate an average information matrix, which 
is used to calculate the genetic correlation value. LDSC uses a similar intuition to the 
univariate case, but instead of single association results being compared to LD scores, 
it is products of the two z-scores, which likewise should, all else being equal, covary 
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with LD score, with larger z products than expected indicating increased genetic 
variance in those regions. 
Polygenic scoring was undertaken using the LDpred (145) package in Python 
(www.python.org) was used for these analyses because of its ability to account for LD 
structure in population samples, and its use of all genetic variants (lack of an arbitrary p-
value threshold for inclusion of the genetic variants in the polygenic score). LDpred 
allows for the modeling of LD based on LD in the discovery sample to weight the 
relative contributions of nearby variants to the outcome phenotype. LDpred uses 
postulated proportions of causal variants in the genome as Bayesian prior probabilities 
for GPS calculations, and a range of 8 different priors were used to construct scores; 
proportions of 1, 0.3, 0.1, 0.03, 0.01, 0.003, and 0.001, as well as the model of infinite 
variants of infinitesimally small effect(128). Using polygenic scores for depressive 
symptoms and neuroticism calculated from summary statistics derived from a large 
meta-analysis of samples from a number of different sources (95) as predictors, 
regressions were run using R (www.r-project.org) to determine prediction of the primary 
outcomes. These scores could not be used validly to predict into the MGS sample, 
however, since MGS was included, as part of the Psychiatric Genomics Consortium 
(146), in the meta-analysis that produced the summary statistics. 
Finally, in order to directly compare the patterns of GAD comorbidity with respect 
to MD versus MD comorbidity with respect to GAD, the method of Breaking Up 
Heterogeneous Mixture Based On Cross-locus correlations (BUHMBOX) was used 
(147). BUHMBOX is designed to detect heterogeneity in the presence of pleiotropy, 
where heterogeneity refers to disease cases having cryptic subgroups that may differ in 
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their genetic architecture from the main group of cases, and pleiotropy refers to the 
association of some genetic variants with more than one outcome. In a sample of 
disease cases, such as those affected with MD, evaluating the correlations between loci 
for another disease, such as schizophrenia, allows a determination of whether there are 
likely to be subgroups of MD that have a similar genetic architecture to schizophrenia. 
This is one application BUHMBOX is used for in the initial paper (147), with a non-
significant result, indicating that (in the tested sample), MD cases had no hidden 
subgroup of individuals with similar genetic architecture to schizophrenia cases, though 
power was limited. 
 
II.  Results: 
Univariate heritability estimates were calculated using both GCTA and LDSC. 
Some estimates were not precise enough to be distinguished from 0. All estimates are 
presented in Table 12. GCTA and LDSC estimates roughly agree, though only 
estimates in CONVERGE reached significance. In CONVERGE, MD and comorbid 
MD+GAD were estimated in the range of 0.2 and 0.25, indicating modest heritability in 
both GCTA and LDSC. Neuroticism was estimated at a lower level still, about 0.1, and 
due to the larger standard errors in LDSC, only reached significance in GCTA. 
Estimates were not significant in MGS or S4S samples, likely due to small sample sizes 
resulting in larger standard errors. Clearly, a heritability estimate that is below 0 or 
greater than 1 is nonsense (though some estimates pass these thresholds in Table 12); 
due to a quirk of LDSC’s estimation methodology, these limits are not firmly fixed, 
leading to occasional impossible estimates. Note, however, that in every case the 
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standard errors are large enough to include potentially sensible values, therefore this 
indicates low precision due to low power, rather than paradoxical heritability values. 
Bivariate estimates were only estimable for CONVERGE outcomes, due to 
sample size and only between neuroticism and the other outcomes, MD and MD+GAD, 
since MD+GAD cases are a subset of MD cases. One of the central questions of the 
genetic correlation between MD and GAD (which only had suitable data in MGS) did not 
produce an estimate, due to insufficient sample size. Moreover, in CONVERGE, the 
correlation between MD and neuroticism also failed to estimate in GCTA, due to the 
information matrix not being invertible. It’s possible that this was due to a separation in 
neuroticism values between MD cases and controls – only a handful of MD cases had 
the lowest values of neuroticism, and no MD controls had the highest values, leading to 
a kind of bimodal distribution conditional on MD status (see Figure 36). The GCTA 
estimate for genetic correlation between the MD+GAD comorbidity and neuroticism was 
0.873 (SE 0.031, p-value for being non-zero: 1.74e-174), suggesting high genetic 
overlap. The LDSC estimate for genetic correlation between MD+GAD and neuroticism 
was 1.134 (SE 0.298, p-value for being non-zero: 1.41e-04), and the genetic correlation 
between MD and neuroticism (successfully estimated in LDSC) was 1.086 (0.214, p-
value for being non-zero: 3.88e-07). As with the univariate estimates, a genetic 
correlation greater than 1 is impossible, but LDSC’s estimation procedures can 
generate these values when underpowered. It is clear that both MD and comorbid 
MD+GAD have substantial (non-zero) genetic correlation with neuroticism, but whether 
the true correlations are high (~0.8) or unity (~1.0) cannot be established in this 
analysis. 
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LDpred polygenic score regression coefficients and p-values can be found in 
Table 13. The eight prior causal allele proportions can be construed as hypotheses 
about the genetic architecture of the discovery phenotype. Note that the exact effect 
estimates are less pertinent than the direction of effect and significance, due to the 
different scales of the polygenic scores and outcomes. The strongest results show 
significant prediction at all or most prior levels. Both depressive symptoms and 
neuroticism polygenic scores displayed strong prediction of phenotypic MD, 
neuroticism, and depressive symptoms, in both CONVERGE and S4S (EUR subgroup). 
The MD+GAD outcome in CONVERGE was additionally predicted by the polygenic 
score for neuroticism but not by the depressive symptoms polygenic score. The EAS 
subgroup of S4S, however, had insufficient sample size for significant effects in any 
outcome.  
BUHMBOX computed levels of positive correlations between MD-associated 
variants in GAD cases, and vice-versa, in the MGS sample, which was the only sample 
containing independent MD and GAD groups. There was moderate evidence for 
heterogeneity in GAD cases with respect to MD (p-value 0.009), and also for pleiotropy 
(Mendelian randomization p-value 3e-05). There was much stronger evidence for 
heterogeneity in MD cases with respect to GAD (p-value 4e-20), as well as pleiotropy 
(Mendelian randomization p-value 5e-19). 
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Table 12. Univariate heritability estimates from GCTA and LDSC 
Sample & Outcome GCTA Estimate (SE, P) LDSC Estimate (SE, P) 
CONVERGE MD 0.225 (0.029, 4.29e-15) 0.256 (0.047, 2.56e-08) 
MGS MD 0.000 (0.186, 0.5) -0.244 (0.248, 0.837) 
CONVERGE MD+GAD 0.227 (0.051, 4.27e-06) 0.233 (0.062, 8.56e-05) 
MGS MD+GAD 0.127 (0.244, 0.301) 0.161 (0.371, 0.332) 
MGS GAD 0.000 (0.225, 0.5) 0.116 (0.359,	  0.373) 
CONVERGE Neuroticism 0.090 (0.028, 6.54e-04) 0.073 (0.046, 0.056) 
MGS Neuroticism 0.000 (0.125, 0.5) 0.141 (0.193, 0.233) 
S4S EAS Neuroticism  0.156 (0.403, 0.349) -2.118 (1.498, 0.921) 
S4S EUR Neuroticism 0.103 (0.128, 0.211) -0.262 (0.228, 0.875) 
S4S EAS Depressive Symptoms 0.000 (0.448, 0.5) 1.373 (1.408, 0.165) 
S4S EUR Depressive Symptoms 0.142 (0.133, 0.143) 0.020 (0.226, 0.465) 
Bold values indicate an estimate significantly different from 0. 
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Figure 36. Stratified histogram of neuroticism values with respect to MD status. 
Red bars indicate quantity of MD controls at each value; blue bars indicate quantity of 
cases.
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Table 13. Associations between LDpred polygenic scores and outcomes at each 
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The columns headed ‘inf’ or with proportions correspond to the tested prior levels. 
Regression coefficients are presented, with p-values in parentheses. 
Bold entries are significant at p-value <0.05.  
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III.  Discussion: 
The aggregate use of genomic information allows singular values to address 
such complicated questions as the degree to which a trait’s variance is attributable to 
additive genetic factors, or the level of genetic overlap between traits. The results in this 
chapter suggest that, broadly speaking, the constellation of genetic signatures of and 
relationships between MD, GAD, neuroticism and depressive symptoms seem to match 
expectations. Heritability estimates for all outcomes were either modestly heritable (0.1-
0.25) or non-significant, in both GCTA and LDSC, which is consistent with most 
previous empirical heritability estimates. Generally, estimates are small for neuroticism 
and GAD-related outcomes in past work, though MD’s heritability in this project was 
smaller than expected: ~0.24 to 0.41 (100), although again, the 0.41 estimate is 
somewhat of an outlier. These estimates, as with most traits, are substantially smaller 
than heritability estimates from the biometrical methods applied largely to twin samples. 
This frequent observation may be due to any combination of a number of contributory 
factors: effect sizes that are smaller than the minimum detectable threshold, or even 
smaller than can ever be detected with significance (101); non-additive interactions 
between genetic loci could be contributing to biometrical heritability estimates (102); 
structural variants that aren’t captured by most genotyping methods; gene-environment 
interplay; genomic imprinting; heritability epigenetic modifications and ‘entirely 
unforeseen sources’ (148). Explorations of these hypotheses in model systems suggest 
that the largest contribution is due to multitudes of small-effect variants (149), with 
substantial contributions of epistatic interactions varying greatly between traits, most of 
which involves more than two loci. Human traits may contain more heritability difficult to 
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assess with methods like GCTA and LDSC, since interactions may be more prevalent 
(such as dominance interaction between alleles at a single locus), rare variants may 
contribute more to trait variance, and certain traits may incorporate more genetic 
networks than traits in model organisms (149). 
Two outcomes and samples that produced genome-wide significant variants in 
Chapter 3 did not display significant heritability using GCTA and LDSC: the GAD 
outcome in the MGS sample, and neuroticism in the S4S EUR subgroup. This is an 
inconsistent set of results only if we assume both types of tests have perfect sensitivity 
and specificity. Unfortunately, this is far from true; both genome-wise association tests 
and genotype-based heritability estimation are prone to not only false positives but false 
negatives as well, and these trends are exacerbated by low power. In this case, while 
it’s possible that there is truly no additive genetic variance in GAD or neuroticism, the 
preponderance of evidence from twin studies (84, 87) suggests that the more likely 
explanation is that the MGS and S4S samples were underpowered to detect modest 
additive genetic variance using GCTA and LDSC. 
Estimation of genetic correlation was, disappointingly, only possible in one of 
three samples (due to sample size), and in two of three pairings (due to 
multicolinearity). Only the genetic correlation of neuroticism with the two dichotomous 
outcomes of MD and comorbid MD+GAD produced results. While estimates varied 
widely from 0.87 to over 1 (non-significantly), it is clear that neuroticism is closely 
genetically related to MD (and GAD), in accordance with the twin literature. Neuroticism 
having a genetic correlation of (approximately) unity with both MD and MD+GAD, 
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further, is consistent with the theory that neuroticism comprises one element of the 
etiological architecture that gives rise to MD and GAD. 
Polygenic risk scoring was somewhat more successful than other approaches, 
producing mostly significant results in a majority of tests. Genetic variants involved in 
the phenotypes of neuroticism and depressive symptoms do a good job of predicting 
within-trait, between one another, and also the disease outcome of MD. Neuroticism, 
but not depressive symptoms, also has a substantial association with comorbid 
MD+GAD in CONVERGE. This suggests that depressive symptoms may be a trait that 
has a closer relationship with depression-specific genetic risk factors than with genetic 
risk factors for GAD, whereas genetic risk factors for neuroticism are related to both MD 
and GAD. 
BUHMBOX results suggest that the heterogeneity of GAD within MD is greater 
than the heterogeneity of MD within GAD, in the MGS sample. The circumstances that 
may jointly explain this include comorbidity (which is clearly true in MGS, with 306 
individuals reporting comorbid MD+GAD), molecular subtypes (there are alternative 
genetic architectures for MD, one or more of which also predispose to GAD), mediated 
pleiotropy or asymmetric causation (having the GAD phenotype is a contributory cause 
of MD onset, more so than the reverse) and ascertainment bias (147). Of these, 
comorbidity is clearly evident, while molecular subtypes and asymmetric causation are 
plausible. Ascertainment bias (specifically that MD cases with GAD were more likely to 
be included in the study) is unlikely, given, as the name suggests, the Molecular 
Genetics of Schizophrenia sample controls were ascertained for (lack of) schizophrenia, 
and not selected for MD status, with comorbid GAD or otherwise.  








MD and GAD are psychiatric disorders that contribute a great deal of misery to 
the world. MD has the 2nd biggest impact on years lived with disability worldwide, with 
anxiety disorders 7th (11). 60% of individuals suffering from MD report at least severe 
role impairment (10), while GAD sabotages global well-being and life satisfaction (15). 
In addition to their effects on quality of life, the two disorders have a pronounced effect 
on mortality as well, mediated by other forms of illness and injury. MD has perhaps the 
larger effect on mortality, increasing the risk of suicide by 11 times (19). GAD makes up 
for this with multiplex effects on morbidity, however, being associated with a wide 
variety of chronic debilitating physiological syndromes, such as pain conditions like 
arthritis, back pain, and migraine (20). Both MD and GAD contribute to heart problems, 
with depression increasing risk of myocardial infarction (16), and GAD predisposing to 
coronary artery disease (22).  
Despite similar presentations being noted during much of recorded history, the 
study of both MD and GAD in psychiatric epidemiology has only been pursued 
systematically since the mid-20th century. During this time, a number of risk factors and 
related constructs have been identified. High-quality romantic relationships, such as 
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happy marriages, are protective against both MD (60) and GAD (72). Stressful life 
events are also powerful contributors to MD (62) and GAD (73). Perhaps most 
significantly, the personality trait of neuroticism has both an epidemiological (50) and a 
latent genetic link (51) to MD and GAD.  
Latent genetic methods such as twin studies have concluded that MD, GAD and 
Neuroticism are moderately heritable (81, 84, 87), and that all three have high-to-
complete overlap in additive genetic factors (51, 86, 89-91). Attempts to find specific 
genetic loci involved in the etiology of these outcomes have begun to bear fruit in recent 
years, with significant variants identified for MD (93, 98), Neuroticism (95), and GAD-
related outcomes (94, 96, 97), though none (until now) for GAD itself. Aggregate genetic 
techniques have estimated heritability for these outcomes as lower than the twin 
estimates, ranging from around 0.1 for neuroticism (95, 104) to as high as 0.41 for MD 
liability (100). As mentioned in the introduction, however, the 0.41 estimate is much 
closer to the twin heritability value for MD than most genotype-based heritability 
methods generally produce, so this may be an unrealistic point of comparison.  
 
The present investigation builds upon this framework of knowledge about the 
etiological architecture of GAD, neuroticism and MD. Analyses to clarify the relative 
strength of psychosocial risk factors were detailed in Chapter 2. Attempts to find specific 
genetic loci involved in these outcomes were reported in Chapter 3. Multiple methods 
were used to quantify the degree of genetic variance in each outcome and also 
relationships between them in Chapter 4. 
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The results in Chapter 2, from the CONVERGE and S4S samples, suggest that 
virtually all tested risk factors were associated with the MD, GAD and related outcomes, 
with broadly aversive predictors increasing risk, and pleasant ones reducing risk. There 
was some evidence of differences in strength of association between subgroups in the 
S4S sample, with relationship satisfaction perhaps providing more protective effect 
against depressive symptoms to males than females (Figure 5). Social support had a 
reverse effect, with a more pronounced negative association in females than males with 
both depressive symptoms and neuroticism, with the association with neuroticism not 
even reaching significance in males (Figure 7). There was also a tendency for protective 
effects to be stronger in the EUR ancestry subgroup than the EAS subgroup, though 
this may be a function of sample size (Figure 7). Overall, the psychosocial factors had a 
weaker effect on a one standard deviation change in neuroticism than on risk of MD, 
MD+GAD, and depressive symptoms. This is consistent with neuroticism comprising a 
portion of the liability to MD (and GAD); in that a difference in psychosocial risk 
(approximately) corresponding to a two standard deviation difference in neuroticism is 
comparable to the increase in psychosocial risk that would predict an MD case based 
on liability, rather than an MD control. 
The results from Chapter 3 include a number of ostensibly significant findings, 
using Bonferroni significance thresholds. The genome-wide association tests produced 
a total of 5 significant loci that may represent true effects among all the samples and 
outcomes. For the CONVERGE sample, two significant loci were detected for the MD 
outcome (Figure 9). The variant rs35936514 was significant for MD (Figure 11), a result 
previously identified in the CONVERGE study (93). The variant rs7257142 had not 
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previously been associated with MD (Figure 12), in the PLIN4 gene, which is related to 
adipocyte functioning. The MGS sample performed surprisingly strongly, producing 2 
loci of interest. Both of these loci were found for the GAD outcome (Figure 21). The first 
variant, rs117420048, is in the intron of LINC00824, a long non-coding RNA on 
chromosome 8 (Figure 23). The other, rs146220192, is found around LINC00348, 
another long non-coding RNA on chromosome 13 (Figure 24). In all S4S outcomes, the 
only significant variant occurred for neuroticism in the EUR subgroup (Figure 33), which 
was rs113888384, in the CRMP1 gene (Figure 35), which is involved in neural 
development, and has been previously implicated in relation to major depression and 
schizophrenia (140). Gene-based results from MAGMA also produced a number of 
associated genes that appeared potentially genuine, mostly in the CONVERGE sample 
(Tables 7-9), though also three for the GAD outcome in MGS (Table 10). None of the 
loci or genes that reached significance were found for more than one outcome, though 
this is not surprising. Even replication within extremely well-matched phenotypes across 
samples is generally rare, in all but the largest meta-analyses to date, so with the 
moderate to low sample sizes in this project, finding common signals for related 
outcomes would be an optimistic expectation. 
In Chapter 4, a number of methods were deployed to compare the overall degree 
of heritability in the outcomes of MD, GAD, neuroticism, and depressive symptoms. 
GCTA and LDSC univariate heritability estimates were only significant in CONVERGE 
(Table 12), suggesting modest heritability for MD and MD+GAD (0.22-0.25), and low 
heritability for neuroticism (0.09, only significant in GCTA). Bivariate genetic correlation 
between outcomes likewise was only successfully estimated in CONVERGE, resulting 
	   115	  
in high-complete overlap in genetic factors neuroticism and both MD and MD+GAD 
outcomes. Polygenic risk score prediction of outcomes using LDpred (Table 13) 
provided additional evidence that neuroticism has some shared genetic factors with MD 
and MD+GAD. The polygenic score for depressive symptoms predicted only itself, 
neuroticism and MD (not MD+GAD). Finally, BUHMBOX suggested increased 
heterogeneity in MD for GAD than in GAD for MD. In other words, there was evidence 
for subgroups of MD in which GAD was prominent, and also asymmetric GAD  MD 
causation, more than the reverse. These results suggest that while there is high overlap 
in genetic factors between MD, GAD, and neuroticism, there are complexities 
nevertheless. For one, the low empirical heritability estimates suggest these outcomes 
are mostly comprised of environmental effects as well as perhaps some portion of non-
additive/non-common genetic effects. Additionally, the failure of the polygenic score for 
depressive symptoms to predict the comorbid MD+GAD outcome, and the asymmetry 
evident in the BUHMBOX results suggests that GAD may have a more prominent 
phenotypic effect on MD risk than the MD phenotype does on GAD risk. 
 
In order to understand what the gestalt import of these results is, it would 
perhaps be helpful to explore a few different possible states of affairs of how MD, GAD 
and neuroticism interrelate. Any future work on interventions in this area, such as 
treatments to help those with MD and GAD, would be more likely to succeed if designed 
with an understanding of the nature of their etiology and comorbidity. Thus, investigation 
into competing models of comorbidity is a basic foundational effort that may inform 
future more applied research. By comparing levels of evidence for different models of 
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comorbidity, one is essentially testing an array of hypotheses, some compatible and 
some mutually exclusive. Ten discrete models will be considered, which have been 
derived mathematically by authoritative prior work (150). Primarily, they will be judged 
on their consistency with the evidence produced in this project as theories about the 
relationship between MD and GAD, with the role of neuroticism to be considered later. 
The basic models include chance comorbidity, sampling bias, population stratification, 
symptom overlap, alternate forms, multiformity, separate comorbidity outcome, 
correlated liabilities, directional causation, and reciprocal causation.  
Comorbidity due to chance results from essentially accidental overlap in 
statistically independent disorders; if there is no correlation, a portion of cases for one 
disorder will stochastically happen to also be cases for the other. This is not likely to 
constitute the relationship between MD and GAD, based on the wealth of statistical and 
genetic work suggesting co-occurrence at much higher than chance rates. 
Sampling bias may contribute to the appearance of comorbidity, when samples 
are (for instance) clinically ascertained and those affected with multiple disorders may 
be more likely to seek or receive treatment. While comorbid MD+GAD does indeed 
result in more severe presentations (25, 26), of the samples used in this project only 
CONVERGE was clinically ascertained for the presence of a psychiatric disorder. It is 
unlikely that ascertainment for MD increased the proportion of comorbid individuals in 
CONVERGE, however, due to the proportion of MD cases with comorbid GAD in 
CONVERGE being approximately 25%, scarcely half the proportion of MD cases with 
GAD in MGS at about 48%. The individuals used from the MGS sample, notably, were 
selected for not having schizophrenia.  
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Population stratification may be another source of spurious comorbidity. If there 
are separate sets of risk factors for two disorders, but both sets happen to have 
increased prevalence in the same segment of the population, the disorders will appear 
to be comorbid. While stratification could be conceived along virtually any sort of 
classifying factor that describes people, many of the common sources, including age 
(life stage), sex, ancestry, and SES (proxied via educational attainment) were included 
in analyses whenever possible in this project. These covariates and stratification 
variables often had an effect on the risk of MD and GAD, but in no case did they explain 
the entirety of the relationship between MD and GAD. This suggests that population 
stratification (while it cannot be completely ruled out), is not the central force driving the 
connection between MD and GAD. 
Symptom overlap could result in comorbidity when some of the same criteria are 
used as decision factors for the diagnosis of two diseases. There are three criteria in the 
DSM diagnoses of major depressive episode (Table 1) and GAD (Table 3) that could be 
construed as overlapping: “Insomnia or Hypersomnia nearly every day [for a two-week 
period]” vs. “Sleep disturbance (difficulty falling or staying asleep, or restless 
unsatisfying sleep) [more days than not for at least 6 months]”; “Fatigue or loss of 
energy nearly every day [for a two-week period]” vs. “Being easily fatigued [more days 
than not for at least 6 months]”; and “Diminished ability to think or concentrate, or 
indecisiveness, nearly every day (either by subjective account or as observed by others) 
[for a two-week period]” vs. “Difficulty concentrating or mind going blank [more days 
than not for at least 6 months].” While the duration and frequency of these symptoms is 
quite dissimilar between MD and GAD criteria, the descriptions are very close. 
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Symptom level data was not available for all subgroups and samples, which means that 
for some comorbid individuals the contribution of this symptom overlap could not be 
assessed. It is possible that these similarities in diagnostic criteria contribute to MD and 
GAD comorbidity, not only in this project, but in existing literature as well. 
Alternate forms is a comorbidity model in which there is a single liability 
distribution associated with both disorders, suggesting that the expression of, for 
instance, MD, GAD, or both MD+GAD would depend on factors that do not affect overall 
liability. There is some support for this model in the literature and in the similar impact of 
all the psychosocial risk factors on both MD and MD+GAD (except perhaps adult 
stressful life events). However, it is inconsistent with comorbid cases suffering 
increased symptoms (due, for instance, to having higher liability load, on average), as 
has been mentioned previously. It is also incompatible with evidence of directional 
phenotypic causation, such as the BUHMBOX results suggesting more pronounced 
GADMD causation. 
The multiformity model of comorbidity posits that one disorder, say MD, is 
responsible for generating the symptoms of another, GAD, despite being unrelated to 
the liability for GAD at all. There are multiple subtypes of this model, depending on 
when the chance of displaying the second constellation of symptoms arises, such as a 
single threshold for disease status and chance of displaying secondary symptoms, or 
two thresholds: the higher corresponding to the secondary presentation (and resulting in 
higher liability in comorbid cases). A gradual increase in risk of GAD symptoms as a 
function of MD liability is also possible. A model in which GAD is only observed as a 
consequence of MD liability is also conceivable. The types of analyses contained in this 
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project are not well-suited for choosing between these models; a statistical effect on risk 
for GAD may indicate an impact on GAD liability, but could instead have an effect on 
MD liability with multiformity for GAD. The only subset of multiformity models that can 
be confidently excluded are those that suggest that one disorder encompasses another 
– the presence of MD cases without GAD, and GAD cases without MD precludes any 
sort of multiformity incompatible with cases of both disorders in absence of the other. 
Models that posit a comorbid condition as a separate outcome qualitatively 
dissimilar from the separate disorders, are, in comparison, quite easy to test. If the 
liability for a comorbid condition (MD+GAD) is independent of liabilities for the individual 
outcomes (MD and GAD), one would not necessarily expect the same risk factors to 
increase risk similarly across multiple outcomes. It’s possible that one (or more) will, but 
this would be random, due to their statistical independence. The similarity of effect of all 
psychosocial risk factors between MD and MD+GAD (with the possible exception of 
adult stressful life events, which had a somewhat stronger association to MD+GAD than 
MD) would argue that a separate MD+GAD liability distribution is unlikely. Also, the 
genetic correlation estimate between MD and neuroticism was near unity, as was the 
correlation between MD+GAD and neuroticism – an unlikely scenario for independent 
outcomes. 
The model of correlated liabilities suggests each disorder has its own liability 
distribution, but an increase in liability on one continuum also constitutes an (often 
diminished) increase in liability on the other. This model is consistent with a high degree 
of similarity in risk factors between MD and GAD, as well as with deviations from perfect 
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matching. This model appears to be perfectly consistent with all findings except 
suggestions of unequal heterogeneity from BUHMBOX. 
Directional causation places some hierarchy on the disorders – their liabilities 
may be separate, with the exception that one disorder is a risk factor for the other. That 
is, the phenotypic state of meeting criteria for one disorder directly increases the risk of 
also having the other. Key to this model is that this relationship is one way. In terms of 
genetic risk factors, this could also be conceived as mediated pleiotropy. The most 
direct support for this model in this project is the GADMD causation suggested by 
BUHMBOX. It is also supported by the failure of the depressive symptoms polygenic 
score (a broad proxy for MD polygenic score) to predict the comorbid MD+GAD 
outcome as well as it predicted the MD outcome. However, the fact that most risk 
factors and genetic correlations behaved identically between MD and MD+GAD would 
suggest that the MD liability may not be meaningfully increased by the addition of GAD. 
This is also the opposite conclusion from one of the best fitting models in the biometrical 
comorbidity paper (150), which found rather that MD tended to cause GAD. 
Finally reciprocal causation is similar to two directional causation models put 
together – it could indeed be symmetric causation, but the two paths need not be equal 
in magnitude. This suggests that there is no direct relationship between the liabilities to 
MD and GAD, but that any statistical link found between them is due to the mediation of 
phenotypic causation. The appearance of MD risk factors having an association with 
GAD is only due to the MD phenotype tending to contribute to onset of a GAD 
phenotype as well. This is another model that the present analyses are not well-suited 
to disprove. The plausibility of this model depends on there being sub-threshold 
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phenotypic effects, however – due to the patterns of familial aggregation between mood 
and anxiety disorders (such as MD and GAD). If the only connection between MD and 
GAD was the impact of full diagnosis of one disorder on the other, there should be no 
cross-disorder familial aggregation (the risk for MD should not contribute to the risk for 
GAD in the absence of MD), but this is well-supported (151). Allowing for phenotypic 
effects of liability levels that fall below the diagnostic threshold would enable this type of 
model to be consistent with the majority of available evidence, however. 
Overall, it seems as though there are a number of comorbidity models that are 
consistent with the observed pattern of results in this project. Various types of 
multiformity, correlated liabilities, and reciprocal causation appear to be the most 
plausible basic models. Of course, there is no theoretical reason that the true 
arrangement of the etiological architecture of MD and GAD couldn’t include aspects of 
multiple of these disorders. The results from the tests of neuroticism, initially included in 
this project as a predictor, then an ancillary continuous outcome, and now as an 
interesting trait in its own right, actually provide a hypothesis. Neuroticism appears to 
function, as far as can be evaluated using the battery of tests in this manuscript, as a 
portion of the liability distribution that is shared between MD and GAD. That is, for the 
range of predictive factors that can be construed as the determinants of neuroticism, the 
model of comorbidity, with MD, GAD and neuroticism that fits best is actually alternate 
forms, in the following sense: neuroticism may only contribute a minority of the overall 
variance in MD or GAD, but there is no neuroticism variance not shared with the other 
outcomes. The ‘liability’ to neuroticism composes a portion of the liability to MD and 
GAD both. The remainder, however, appears to be consistent with a correlated liabilities 
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model, in that genetic and environmental correlation estimates from biometrical 
methods (the present project could not directly estimate an MD-GAD genetic 
correlation) suggest high similarity. There is also evidence, however, of both MDGAD 
causation (150), and GADMD causation (BUHMBOX mediated pleiotropy, and 
asymmetric performance of depressive symptoms polygenic score).  
Thus, the most plausible model from all available data appears to be a core of 
common etiology shared entirely between MD and GAD, of which neuroticism is an 
important component. The remainder of the risk structure for MD and GAD are 
correlated liability distributions, in which the phenotype (perhaps even sub-threshold) of 
each disorder acts as a risk factor for the other, though the relative magnitude of these 
effects is as yet unknown.  
This project has a number of important limitations that are vital to be aware of 
when evaluating its conclusions. First, the sample size, as has been mentioned 
throughout, and therefore statistical power, varied widely in adequacy from perfectly 
appropriate for psychosocial tests in CONVERGE, to insufficient for estimation for most 
bivariate aggregate genetic methods. Second, replication (and meta-analysis) between 
samples was largely impossible, due to the overlapping ancestry and data compositions 
– all findings should therefore be viewed as preliminary until they can be validated with 
further research. Third, there were methodological differences between samples that 
could only be highlighted rather than controlled, and therefore there may be bias due to 
different ascertainment, assessment, and quality control procedures in the component 
datasets beyond presently tractable adjustment strategies.  
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Finally, some of the central questions of the study – to what degree do the 
genetic and psychosocial risk dimensions of MD and GAD overlap, could not be asked 
with the available data, and conclusions are therefore based on indirect evidence and 
past work – future work will be vital to determining whether these conclusions hold. 
 
The dual faces of misery present many obstacles to understanding, due to their 
inscrutable origins and pernicious, prevalent influence. We should not, however, 
relinquish hope. In the enigmatic strength of their divided unity, there is a kind of 
vulnerability; it is highly likely that when we finally unmask the foundation of one 
disorder, the principal essence of the other will be revealed as well.
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